Meta-Analysis
doi: 10.1002/14651858.CD006531.pub2.
Paroxetine versus other anti-depressive agents for depression
Affiliations
- PMID: 24696195
- PMCID: PMC10091826
- DOI: 10.1002/14651858.CD006531.pub2
Item in Clipboard
Meta-Analysis
Paroxetine versus other anti-depressive agents for depression
Cochrane Database Syst Rev.
.
Abstract
Background: Paroxetine is the most potent inhibitor of the reuptake of serotonin of all selective serotonin reuptake inhibitors (SSRIs) and has been studied in many randomised controlled trials (RCTs). However, these comparative studies provided contrasting findings and systematic reviews of RCTs have always considered the SSRIs as a group, and evidence applicable to this group of drugs might not be applicable to paroxetine alone. The present systematic review assessed the efficacy and tolerability profile of paroxetine in comparison with tricyclics (TCAs), SSRIs and newer or non-conventional agents.
Objectives: 1. To determine the efficacy of paroxetine in comparison with other anti-depressive agents in alleviating the acute symptoms of Major Depressive Disorder.2. To review acceptability of treatment with paroxetine in comparison with other anti-depressive agents.3. To investigate the adverse effects of paroxetine in comparison with other anti-depressive agents.
Search methods: We searched the Cochrane Depression, Anxiety and Neurosis Review Group's Specialized Register (CCDANCTR, to 30 September 2012), which includes relevant randomised controlled trials from the following bibliographic databases: The Cochrane Library (all years), EMBASE (1974 to date), MEDLINE (1950 to date) and PsycINFO (1967 to date). Reference lists of relevant papers and previous systematic reviews were handsearched. Pharmaceutical companies marketing paroxetine and experts in this field were contacted for supplemental data.
Selection criteria: All randomised controlled trials allocating participants with major depression to paroxetine versus any other antidepressants (ADs), both conventional (such as TCAs, SSRIs) and newer or non-conventional (such as hypericum). For trials which had a cross-over design, only results from the first randomisation period were considered.
Data collection and analysis: Two review authors independently checked eligibility and extracted data using a standard form. Data were then entered in RevMan 5.2 with a double-entry procedure. Information extracted included study and participant characteristics, intervention details, settings and efficacy, acceptability and tolerability measures.
Main results: A total of 115 randomised controlled trials (26,134 participants) were included. In 54 studies paroxetine was compared with older ADs, in 21 studies with another SSRI, and in 40 studies with a newer or non-conventional antidepressant other than SSRIs. For the primary outcome (patients who responded to treatment), paroxetine was more effective than reboxetine at increasing patients who responded early to treatment (Odds Ratio (OR): 0.66, 95% Confidence Interval (CI) 0.50 to 0.87, number needed to treat to provide benefit (NNTb) = 16, 95% CI 10 to 50, at one to four weeks, 3 RCTs, 1375 participants, moderate quality of evidence), and less effective than mirtazapine (OR: 2.39, 95% CI 1.42 to 4.02, NNTb = 8, 95% CI 5 to 14, at one to four weeks, 3 RCTs, 726 participants, moderate quality of evidence). Paroxetine was less effective than citalopram in improving response to treatment (OR: 1.54, 95% CI 1.04 to 2.28, NNTb = 9, 95% CI 5 to 102, at six to 12 weeks, 1 RCT, 406 participants, moderate quality of evidence). We found no clear evidence that paroxetine was more or less effective compared with other antidepressants at increasing response to treatment at acute (six to 12 weeks), early (one to four weeks), or longer term follow-up (four to six months). Paroxetine was associated with a lower rate of adverse events than amitriptyline, imipramine and older ADs as a class, but was less well tolerated than agomelatine and hypericum. Included studies were generally at unclear or high risk of bias due to poor reporting of allocation concealment and blinding of outcome assessment, and incomplete reporting of outcomes.
Authors' conclusions: Some possibly clinically meaningful differences between paroxetine and other ADs exist, but no definitive conclusions can be drawn from these findings. In terms of response, there was a moderate quality of evidence that citalopram was better than paroxetine in the acute phase (six to 12 weeks), although only one study contributed data. In terms of early response to treatment (one to four weeks) there was moderate quality of evidence that mirtazapine was better than paroxetine and that paroxetine was better than reboxetine. However there was no clear evidence that paroxetine was better or worse compared with other antidepressants at increasing response to treatment at any time point. Even if some differences were identified, the findings from this review are better thought as hypothesis forming rather than hypothesis testing and it would be reassuring to see the conclusions replicated in future trials. Finally, most of included studies were at unclear or high risk of bias, and were sponsored by the drug industry. The potential for overestimation of treatment effect due to sponsorship bias should be borne in mind.
Conflict of interest statement
MP, CG, DP, CT, LRM, CR, CB, AC: none.
TAF has received honoraria for speaking at CME meetings sponsored by Asahi Kasei, Eli Lilly, GlaxoSmithKline, Mochida, MSD, Otsuka, Pfizer, Shionogi and Tanabe‐Mitsubishi. He is diplomate of the Academy of Cognitive Therapy. He has received royalties from Igaku‐Shoin, Seiwa‐Shoten and Nihon Bunka Kagaku‐sha. He is on advisory board for Sekisui Chemicals and Takeda Science Foundation. The Japanese Ministry of Education, Science, and Technology, the Japanese Ministry of Health, Labor and Welfare, and the Japan Foundation for Neuroscience and Mental Health have funded his research projects.
NW has received research grants from the Japanese Ministry of Education, Science, Sports and Culture; and from the Japanese Ministry of the Health, Labour and Welfare. He has also received speaking fees and research funds from Asahi Kasei, Dai‐Nippon Sumitomo, Eli Lilly, GlaxoSmithKline, Janssen, MSD, Otsuka, Pfizer and Schering‐Plough.
Figures
Flow diagram.
'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.
'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
Comparison 1 Failure to respond at endpoint (6 ‐ 12 weeks), Outcome 1 Paroxetine versus older ADs.
Comparison 1 Failure to respond at endpoint (6 ‐ 12 weeks), Outcome 2 Paroxetine versus other SSRIs.
Comparison 1 Failure to respond at endpoint (6 ‐ 12 weeks), Outcome 3 Paroxetine versus newer or non‐conventional ADs.
Comparison 2 Failure to respond (at 1 ‐ 4 weeks), Outcome 1 Paroxetine versus older ADs.
Comparison 2 Failure to respond (at 1 ‐ 4 weeks), Outcome 2 Paroxetine versus SSRIs.
Comparison 2 Failure to respond (at 1 ‐ 4 weeks), Outcome 3 Paroxetine versus newer or non‐conventional ADs.
Comparison 3 Failure to respond (at 16 ‐ 24 weeks), Outcome 1 Paroxetine versus SSRIs.
Comparison 3 Failure to respond (at 16 ‐ 24 weeks), Outcome 2 Paroxetine versus newer or non‐conventional ADs.
Comparison 4 Failure to remit at endpoint (6 ‐ 12 weeks), Outcome 1 Paroxetine versus older ADs.
Comparison 4 Failure to remit at endpoint (6 ‐ 12 weeks), Outcome 2 Paroxetine versus other SSRIs.
Comparison 4 Failure to remit at endpoint (6 ‐ 12 weeks), Outcome 3 Paroxetine versus newer or non‐conventional ADs.
Comparison 5 Failure to remit (at 1 ‐ 4 weeks), Outcome 1 Paroxetine versus older ADs.
Comparison 5 Failure to remit (at 1 ‐ 4 weeks), Outcome 2 Paroxetine versus other SSRIs.
Comparison 5 Failure to remit (at 1 ‐ 4 weeks), Outcome 3 Paroxetine versus newer or non‐conventional ADs.
Comparison 6 Failure to remit (at 16 ‐ 24 weeks), Outcome 1 Paroxetine versus newer or non‐conventional ADs.
Comparison 7 Standardized mean difference at endpoint (6 ‐ 12 weeks), Outcome 1 Paroxetine versus older ADs.
Comparison 7 Standardized mean difference at endpoint (6 ‐ 12 weeks), Outcome 2 Paroxetine versus other SSRIs.
Comparison 7 Standardized mean difference at endpoint (6 ‐ 12 weeks), Outcome 3 Paroxetine versus newer or non‐conventional ADs.
Comparison 8 Standardized mean difference (at 1 ‐ 4 weeks), Outcome 1 Paroxetine versus older ADs.
Comparison 8 Standardized mean difference (at 1 ‐ 4 weeks), Outcome 2 Paroxetine versus other SSRIs.
Comparison 8 Standardized mean difference (at 1 ‐ 4 weeks), Outcome 3 Paroxetine versus newer or non‐conventional ADs.
Comparison 9 Standardized mean difference (at 16 ‐ 24 weeks), Outcome 1 Paroxetine versus SSRIs.
Comparison 9 Standardized mean difference (at 16 ‐ 24 weeks), Outcome 2 Paroxetine versus newer or non‐conventional ADs.
Comparison 10 Failure to complete (any cause), Outcome 1 Paroxetine versus older ADs.
Comparison 10 Failure to complete (any cause), Outcome 2 Paroxetine versus other SSRIs.
Comparison 10 Failure to complete (any cause), Outcome 3 Paroxetine versus newer or non‐conventional ADs.
Comparison 11 Failure to complete (due to inefficacy), Outcome 1 Paroxetine versus older ADs.
Comparison 11 Failure to complete (due to inefficacy), Outcome 2 Paroxetine versus other SSRIs.
Comparison 11 Failure to complete (due to inefficacy), Outcome 3 Paroxetine versus newer or non‐conventional ADs.
Comparison 12 Failure to complete (due to side effects), Outcome 1 Paroxetine versus older ADs.
Comparison 12 Failure to complete (due to side effects), Outcome 2 Paroxetine versus other SSRIs.
Comparison 12 Failure to complete (due to side effects), Outcome 3 Paroxetine versus newer or non‐conventional ADs.
Comparison 13 SE ‐ Participants with at least one TEAE, Outcome 1 Paroxetine versus older ADs.
Comparison 13 SE ‐ Participants with at least one TEAE, Outcome 2 Paroxetine versus other SSRIs.
Comparison 13 SE ‐ Participants with at least one TEAE, Outcome 3 Paroxetine versus newer or non‐conventional ADs.
Comparison 14 SE ‐ Abnormal dreams, Outcome 1 Paroxetine versus older ADs.
Comparison 14 SE ‐ Abnormal dreams, Outcome 2 Paroxetine versus other SSRIs.
Comparison 14 SE ‐ Abnormal dreams, Outcome 3 Paroxetine versus newer or non‐conventional ADs.
Comparison 15 SE ‐ Abnormal laboratory values, Outcome 1 Abnormal white blood cells.
Comparison 15 SE ‐ Abnormal laboratory values, Outcome 2 Leucocytosis.
Comparison 15 SE ‐ Abnormal laboratory values, Outcome 3 ALT/AST increase.
Comparison 15 SE ‐ Abnormal laboratory values, Outcome 4 NOS.
Comparison 16 SE ‐ Abnormal thinking, Outcome 1 Paroxetine versus newer or non‐conventional ADs.
Comparison 17 SE ‐ Accidental injury, Outcome 1 Paroxetine versus other SSRIs.
Comparison 17 SE ‐ Accidental injury, Outcome 2 Paroxetine versus newer or non‐conventional ADs.
Comparison 18 SE ‐ Agitation/anxiety, Outcome 1 Paroxetine versus older ADs.
Comparison 18 SE ‐ Agitation/anxiety, Outcome 2 Paroxetine versus other SSRIs.
Comparison 18 SE ‐ Agitation/anxiety, Outcome 3 Paroxetine versus newer or non‐conventional ADs.
Comparison 19 SE ‐ Akathisia, Outcome 1 Paroxetine versus older ADs.
Comparison 19 SE ‐ Akathisia, Outcome 2 Paroxetine versus newer or non‐conventional ADs.
Comparison 20 SE ‐ Anorexia, Outcome 1 Paroxetine versus other SSRIs.
Comparison 20 SE ‐ Anorexia, Outcome 2 Paroxetine versus newer or non‐conventional ADs.
Comparison 21 SE ‐ Anticholinergic, Outcome 1 paroxetine versus older ADs.
Comparison 21 SE ‐ Anticholinergic, Outcome 2 paroxerine versus other SSRIs.
Comparison 22 SE ‐ Appetite decreased, Outcome 1 Paroxetine versus older ADs.
Comparison 22 SE ‐ Appetite decreased, Outcome 2 Paroxetine versus other SSRIs.
Comparison 22 SE ‐ Appetite decreased, Outcome 3 Paroxetine versus newer or non‐conventional ADs.
Comparison 23 SE ‐ Appetite increased, Outcome 1 Paroxetine versus newer or non‐conventional ADs.
Comparison 24 SE ‐ Asthenia, Outcome 1 Paroxetine versus older ADs.
Comparison 24 SE ‐ Asthenia, Outcome 2 Paroxetine versus other SSRIs.
Comparison 24 SE ‐ Asthenia, Outcome 3 Paroxetine versus newer ADs.
Comparison 25 SE ‐ Behaviour, Outcome 1 Euphoria.
Comparison 25 SE ‐ Behaviour, Outcome 2 Hostility.
Comparison 25 SE ‐ Behaviour, Outcome 3 Impulsive.
Comparison 25 SE ‐ Behaviour, Outcome 4 Irritability.
Comparison 25 SE ‐ Behaviour, Outcome 5 Paranoid reaction.
Comparison 25 SE ‐ Behaviour, Outcome 6 Psychotic symptoms.
Comparison 26 SE ‐ Body as a whole, Outcome 1 Paroxetine versus older ADs.
Comparison 26 SE ‐ Body as a whole, Outcome 2 Paroxetine versus other SSRIs.
Comparison 27 SE ‐ Bronchitis, Outcome 1 Paroxetine versus other SSRIs.
Comparison 27 SE ‐ Bronchitis, Outcome 2 Paroxetine versus newer or non‐conventional ADs.
Comparison 28 SE ‐ Cardiovascular system, Outcome 1 Syncope.
Comparison 28 SE ‐ Cardiovascular system, Outcome 2 NOS.
Comparison 29 SE ‐ Chills, Outcome 1 Paroxetine versus newer or non‐conventional ADs.
Comparison 30 SE ‐ Confusion, Outcome 1 Paroxetine versus older ADs.
Comparison 30 SE ‐ Confusion, Outcome 2 Paroxetine versus newer or non‐conventional ADs.
Comparison 31 SE ‐ Constipation, Outcome 1 Paroxetine versus older ADs.
Comparison 31 SE ‐ Constipation, Outcome 2 Paroxetine versus other SSRIs.
Comparison 31 SE ‐ Constipation, Outcome 3 Paroxetine versus newer or non‐conventional ADs.
Comparison 32 SE ‐ Cough, Outcome 1 Paroxetine versus older ADs.
Comparison 32 SE ‐ Cough, Outcome 2 Paroxetine versus newer or non‐conventional ADs.
Comparison 33 SE ‐ Delirium, Outcome 1 Paroxetine versus other SSRIs.
Comparison 33 SE ‐ Delirium, Outcome 2 Paroxetine versus older ADs.
Comparison 34 SE ‐ Depersonalization, Outcome 1 Paroxetine versus older ADs.
Comparison 34 SE ‐ Depersonalization, Outcome 2 Paroxetine versus other SSRIs.
Comparison 34 SE ‐ Depersonalization, Outcome 3 Paroxetine versus newer or non‐conventional ADs.
Comparison 35 SE ‐ Depression, Outcome 1 Paroxetine versus older ADs.
Comparison 35 SE ‐ Depression, Outcome 2 Paroxetine versus other SSRIs.
Comparison 35 SE ‐ Depression, Outcome 3 Paroxetine versus newer or non‐conventional ADs.
Comparison 36 SE ‐ Diarrhoea, Outcome 1 Paroxetine versus older ADs.
Comparison 36 SE ‐ Diarrhoea, Outcome 2 Paroxetine versus other SSRIs.
Comparison 36 SE ‐ Diarrhoea, Outcome 3 Paroxetine versus newer or non‐conventional ADs.
Comparison 37 SE ‐ Dizziness, Outcome 1 Paroxetine versus older ADs.
Comparison 37 SE ‐ Dizziness, Outcome 2 Paroxetine versus other SSRIs.
Comparison 37 SE ‐ Dizziness, Outcome 3 Paroxetine versus newer or non‐conventional ADs.
Comparison 38 SE ‐ Dry mouth, Outcome 1 Paroxetine versus older ADs.
Comparison 38 SE ‐ Dry mouth, Outcome 2 Paroxetine versus other SSRIs.
Comparison 38 SE ‐ Dry mouth, Outcome 3 Paroxetine versus newer or non‐conventional ADs.
Comparison 39 SE ‐ Dyspepsia, Outcome 1 Paroxetine versus older ADs.
Comparison 39 SE ‐ Dyspepsia, Outcome 2 Paroxetine versus other SSRIs.
Comparison 39 SE ‐ Dyspepsia, Outcome 3 Paroxetine versus newer or non‐conventional ADs.
Comparison 40 SE ‐ Dyspnea, Outcome 1 Paroxetine versus older ADs.
Comparison 40 SE ‐ Dyspnea, Outcome 2 Paroxetine versus other SSRIs.
Comparison 40 SE ‐ Dyspnea, Outcome 3 Paroxetine versus newer or non‐conventional ADs.
Comparison 41 SE ‐ ECG abnormailities, Outcome 1 Paroxetine versus older ADs.
Comparison 42 SE ‐ Emotional lability, Outcome 1 Paroxetine versus older ADs.
Comparison 42 SE ‐ Emotional lability, Outcome 2 Paroxetine versus other SSRIs.
Comparison 42 SE ‐ Emotional lability, Outcome 3 Paroxetine versus newer or non‐conventional ADs.
Comparison 43 SE ‐ Fatigue, Outcome 1 Paroxetine versus older ADs.
Comparison 43 SE ‐ Fatigue, Outcome 2 Paroxetine versus other SSRIs.
Comparison 43 SE ‐ Fatigue, Outcome 3 Paroxetine versus newer or non‐conventional ADs.
Comparison 44 SE ‐ Fever, Outcome 1 Paroxetine versus older ADs.
Comparison 44 SE ‐ Fever, Outcome 2 Paroxetine versus newer or non‐conventional ADs.
Comparison 45 SE ‐ Flatulence, Outcome 1 Paroxetine versus older ADs.
Comparison 45 SE ‐ Flatulence, Outcome 2 Paroxetine versus other SSRIs.
Comparison 45 SE ‐ Flatulence, Outcome 3 Paroxetine versus newer or non‐conventional ADs.
Comparison 46 SE ‐ Gastrointestinal disorder, Outcome 1 Appendicitis.
Comparison 46 SE ‐ Gastrointestinal disorder, Outcome 2 Cholelithiasis.
Comparison 46 SE ‐ Gastrointestinal disorder, Outcome 3 Colitis.
Comparison 46 SE ‐ Gastrointestinal disorder, Outcome 4 Eructation.
Comparison 46 SE ‐ Gastrointestinal disorder, Outcome 5 Melena.
Comparison 46 SE ‐ Gastrointestinal disorder, Outcome 6 Gastritis.
Comparison 46 SE ‐ Gastrointestinal disorder, Outcome 7 Gastroenteritis.
Comparison 46 SE ‐ Gastrointestinal disorder, Outcome 8 Intestinal obstruction.
Comparison 46 SE ‐ Gastrointestinal disorder, Outcome 9 Intestinal perforation.
Comparison 46 SE ‐ Gastrointestinal disorder, Outcome 10 Peptic ulcer hemorrhage.
Comparison 46 SE ‐ Gastrointestinal disorder, Outcome 11 NOS.
Comparison 47 SE ‐ Gynecological, Outcome 1 Dysmenorrhea.
Comparison 47 SE ‐ Gynecological, Outcome 2 Mestrual disorder.
Comparison 47 SE ‐ Gynecological, Outcome 3 Vaginal moniliasis.
Comparison 47 SE ‐ Gynecological, Outcome 4 Ectopic pregnancy.
Comparison 47 SE ‐ Gynecological, Outcome 5 Polycystic granuloma.
Comparison 48 SE ‐ Headache, Outcome 1 Paroxetine versus older ADs.
Comparison 48 SE ‐ Headache, Outcome 2 Paroxetine versus other SSRIs.
Comparison 48 SE ‐ Headache, Outcome 3 Paroxetine versus newer or non‐conventional ADs.
Comparison 49 SE ‐ Hypertension, Outcome 1 Paroxetine versus older ADs.
Comparison 49 SE ‐ Hypertension, Outcome 2 Paroxetine versus other SSRIs.
Comparison 49 SE ‐ Hypertension, Outcome 3 Paroxetine versus newer or non‐conventional ADs.
Comparison 50 SE ‐ Hypotension, Outcome 1 Paroxetine versus older ADs.
Comparison 50 SE ‐ Hypotension, Outcome 2 Paroxetine versus other SSRIs.
Comparison 50 SE ‐ Hypotension, Outcome 3 Paroxetine versus newer or non‐conventional ADs.
Comparison 50 SE ‐ Hypotension, Outcome 4 Postural hypotension.
Comparison 51 SE ‐ Hypertonia, Outcome 1 Paroxetine versus newer or non‐conventional ADs.
Comparison 52 SE ‐ Infection, Outcome 1 Meningitis.
Comparison 52 SE ‐ Infection, Outcome 2 Otitis media.
Comparison 52 SE ‐ Infection, Outcome 3 Respiratory upper.
Comparison 52 SE ‐ Infection, Outcome 4 Urinary.
Comparison 52 SE ‐ Infection, Outcome 5 NOS.
Comparison 53 SE ‐ Influenza‐like symptoms, Outcome 1 Paroxetine versus newer or non‐conventional ADs.
Comparison 54 SE ‐ Insomnia, Outcome 1 Paroxetine versus older ADs.
Comparison 54 SE ‐ Insomnia, Outcome 2 Paroxetine versus other SSRIs.
Comparison 54 SE ‐ Insomnia, Outcome 3 Paroxetine versus newer or non‐conventional ADs.
Comparison 55 SE ‐ Metabolic and nutritional system, Outcome 1 Paroxetine versus older ADs.
Comparison 55 SE ‐ Metabolic and nutritional system, Outcome 2 Paroxetine versus other SSRIs.
Comparison 55 SE ‐ Metabolic and nutritional system, Outcome 3 Paroxetine versus newer or non‐conventional ADs.
Comparison 56 SE ‐ Musculoskeletal and connective tissue disorders, Outcome 1 Paroxetine versus older ADs.
Comparison 56 SE ‐ Musculoskeletal and connective tissue disorders, Outcome 2 Paroxetine versus newer or non‐conventional ADs.
Comparison 57 SE ‐ Myalgia, Outcome 1 Paroxetine versus other SSRIs.
Comparison 57 SE ‐ Myalgia, Outcome 2 Paroxetine versus newer or non‐conventional ADs.
Comparison 58 SE ‐ Nervousness, Outcome 1 Paroxetine versus older ADs.
Comparison 58 SE ‐ Nervousness, Outcome 2 Paroxetine versus other SSRIs.
Comparison 58 SE ‐ Nervousness, Outcome 3 Paroxetine versus newer or non‐conventional ADs.
Comparison 59 SE ‐ Nausea/vomiting, Outcome 1 Paroxetine versus older ADs.
Comparison 59 SE ‐ Nausea/vomiting, Outcome 2 Paroxetine versus other SSRIs.
Comparison 59 SE ‐ Nausea/vomiting, Outcome 3 Paroxetine versus newer or non‐conventional ADs.
Comparison 60 SE ‐ Neoplasm, Outcome 1 Basal cell carcinoma.
Comparison 60 SE ‐ Neoplasm, Outcome 2 Bone.
Comparison 60 SE ‐ Neoplasm, Outcome 3 Meningioma.
Comparison 60 SE ‐ Neoplasm, Outcome 4 Pulmonary.
Comparison 60 SE ‐ Neoplasm, Outcome 5 NOS.
Comparison 61 SE ‐ Nervous system, Outcome 1 Amnesia.
Comparison 61 SE ‐ Nervous system, Outcome 2 Concentration impaired.
Comparison 61 SE ‐ Nervous system, Outcome 3 Hyperesthesia.
Comparison 61 SE ‐ Nervous system, Outcome 4 Parkinsonism.
Comparison 61 SE ‐ Nervous system, Outcome 5 Seizure.
Comparison 61 SE ‐ Nervous system, Outcome 6 Stroke.
Comparison 61 SE ‐ Nervous system, Outcome 7 NOS.
Comparison 62 SE ‐ Pain (back), Outcome 1 Paroxetine versus older ADs.
Comparison 62 SE ‐ Pain (back), Outcome 2 Paroxetine versus other SSRIs.
Comparison 62 SE ‐ Pain (back), Outcome 3 Paroxetine versus newer or non‐conventional ADs.
Comparison 63 SE ‐ Pain (chest), Outcome 1 Paroxetine versus older ADs.
Comparison 63 SE ‐ Pain (chest), Outcome 2 Paroxetine versus other SSRIs.
Comparison 63 SE ‐ Pain (chest), Outcome 3 Paroxetine versus newer or non‐conventional ADs.
Comparison 64 SE ‐ Pain (abdominal), Outcome 1 Paroxetine versus older ADs.
Comparison 64 SE ‐ Pain (abdominal), Outcome 2 Paroxetine versus other SSRIs.
Comparison 64 SE ‐ Pain (abdominal), Outcome 3 Paroxetine versus newer or non‐conventional ADs.
Comparison 65 SE ‐ Pain (general), Outcome 1 Paroxetine versus older ADs.
Comparison 65 SE ‐ Pain (general), Outcome 2 Paroxetine versus SSRIs.
Comparison 65 SE ‐ Pain (general), Outcome 3 Paroxetine versus newer or non‐conventional ADs.
Comparison 66 SE ‐ Pain (neck), Outcome 1 Paroxetine versus newer or non‐conventional ADs.
Comparison 67 SE ‐ Palpitations, Outcome 1 Paroxetine versus older ADs.
Comparison 67 SE ‐ Palpitations, Outcome 2 Paroxetine versus other SSRIs.
Comparison 67 SE ‐ Palpitations, Outcome 3 Paroxetine versus newer or non‐conventional ADs.
Comparison 68 SE ‐ Paraesthesia, Outcome 1 Paroxetine versus older ADs.
Comparison 68 SE ‐ Paraesthesia, Outcome 2 Paroxetine versus SSRIs.
Comparison 68 SE ‐ Paraesthesia, Outcome 3 Paroxetine versus newer or non‐conventional ADs.
Comparison 69 SE ‐ Pharyngitis, Outcome 1 Paroxetine versus older ADs.
Comparison 69 SE ‐ Pharyngitis, Outcome 2 Paroxetine versus SSRIs.
Comparison 69 SE ‐ Pharyngitis, Outcome 3 Paroxetine versus newer or non‐conventional ADs.
Comparison 70 SE ‐ Pruritus, Outcome 1 Paroxetine versus other SSRIs.
Comparison 70 SE ‐ Pruritus, Outcome 2 Paroxetine versus newer or non‐conventional ADs.
Comparison 71 SE ‐ RARE, Outcome 1 Abdomen enlarged.
Comparison 71 SE ‐ RARE, Outcome 2 Acute pyelonephritis.
Comparison 71 SE ‐ RARE, Outcome 3 Alcohol abuse.
Comparison 71 SE ‐ RARE, Outcome 4 Angina attack.
Comparison 71 SE ‐ RARE, Outcome 5 Coronary artery disorder.
Comparison 71 SE ‐ RARE, Outcome 6 Deep thrombophlebitis.
Comparison 71 SE ‐ RARE, Outcome 7 Edema generalized.
Comparison 71 SE ‐ RARE, Outcome 8 Balance difficulty.
Comparison 71 SE ‐ RARE, Outcome 9 Enucleation of eyeball.
Comparison 71 SE ‐ RARE, Outcome 10 Epistaxis.
Comparison 71 SE ‐ RARE, Outcome 11 Falls.
Comparison 71 SE ‐ RARE, Outcome 12 Hiccup.
Comparison 71 SE ‐ RARE, Outcome 13 Hot flushes.
Comparison 71 SE ‐ RARE, Outcome 14 Hyperkinesia.
Comparison 71 SE ‐ RARE, Outcome 15 Incoordination.
Comparison 71 SE ‐ RARE, Outcome 16 Irregular pulse.
Comparison 71 SE ‐ RARE, Outcome 17 Light headedness.
Comparison 71 SE ‐ RARE, Outcome 18 Malaise.
Comparison 71 SE ‐ RARE, Outcome 19 Overdose.
Comparison 71 SE ‐ RARE, Outcome 20 Peripheal vascular disorder.
Comparison 71 SE ‐ RARE, Outcome 21 Pregnancy.
Comparison 71 SE ‐ RARE, Outcome 22 Psychosomatic disorders.
Comparison 71 SE ‐ RARE, Outcome 23 Renal failure.
Comparison 71 SE ‐ RARE, Outcome 24 Stage 1 coma.
Comparison 71 SE ‐ RARE, Outcome 25 Tooth disorder.
Comparison 71 SE ‐ RARE, Outcome 26 Voice alteration.
Comparison 72 SE ‐ Rash, itching, allergic reactions, Outcome 1 Paroxetine verus older ADs.
Comparison 72 SE ‐ Rash, itching, allergic reactions, Outcome 2 Paroxetine versus other SSRIs.
Comparison 72 SE ‐ Rash, itching, allergic reactions, Outcome 3 Paroxetine versus newer or non‐conventional ADs.
Comparison 73 SE ‐ Respiratory disorder, Outcome 1 Paroxetine versus older ADs.
Comparison 73 SE ‐ Respiratory disorder, Outcome 2 Paroxetine versus other SSRIs.
Comparison 74 SE ‐ Restlessness, Outcome 1 Paroxetine versus SSRIs.
Comparison 74 SE ‐ Restlessness, Outcome 2 Paroxetine versus newer or non‐conventional ADs.
Comparison 75 SE ‐ Rhinitis, Outcome 1 Paroxetine versus older ADs.
Comparison 75 SE ‐ Rhinitis, Outcome 2 Paroxetine versus SSRIs.
Comparison 75 SE ‐ Rhinitis, Outcome 3 Paroxetine versus newer or non‐conventional ADs.
Comparison 76 SE ‐ Sexual problems, Outcome 1 Anorgasmia.
Comparison 76 SE ‐ Sexual problems, Outcome 2 Ejaculation disorder.
Comparison 76 SE ‐ Sexual problems, Outcome 3 Impotence.
Comparison 76 SE ‐ Sexual problems, Outcome 4 Libido decreased.
Comparison 76 SE ‐ Sexual problems, Outcome 5 Penis disorder.
Comparison 76 SE ‐ Sexual problems, Outcome 6 NOS.
Comparison 77 SE ‐ Skin and appendages, Outcome 1 Paroxetine versus older ADs.
Comparison 77 SE ‐ Skin and appendages, Outcome 2 Paroxetine versus other SSRIs.
Comparison 77 SE ‐ Skin and appendages, Outcome 3 Paroxetine versus newer or non‐conventional ADs.
Comparison 78 SE ‐ Sleep disorders, Outcome 1 Paroxetine versus older ADs.
Comparison 78 SE ‐ Sleep disorders, Outcome 2 Paroxetine versus newer or non‐conventional ADs.
Comparison 79 SE ‐ Sleepiness/drowsiness, Outcome 1 Paroxetine versus older ADs.
Comparison 79 SE ‐ Sleepiness/drowsiness, Outcome 2 Paroxetine versus other SSRIs.
Comparison 79 SE ‐ Sleepiness/drowsiness, Outcome 3 Paroxetine versus newer or non‐conventional ADs.
Comparison 80 SE ‐ Sinusitis, Outcome 1 Paroxetine versus newer or non‐conventional ADs.
Comparison 81 SE ‐ Special senses, Outcome 1 NOS.
Comparison 81 SE ‐ Special senses, Outcome 2 Taste perversion.
Comparison 81 SE ‐ Special senses, Outcome 3 Auditory disorders.
Comparison 82 SE ‐ Surgical procedure, Outcome 1 Paroxetine versus older ADs.
Comparison 82 SE ‐ Surgical procedure, Outcome 2 Paroxetine versus other SSRIs.
Comparison 83 SE ‐ Sweating, Outcome 1 Paroxetine versus older ADs.
Comparison 83 SE ‐ Sweating, Outcome 2 Paroxetine versus other SSRIs.
Comparison 83 SE ‐ Sweating, Outcome 3 Paroxetine versus newer or non‐conventional ADs.
Comparison 84 SE ‐ Tachycardia, Outcome 1 Paroxetine versus older ADs.
Comparison 84 SE ‐ Tachycardia, Outcome 2 Paroxetine versus SSRIs.
Comparison 84 SE ‐ Tachycardia, Outcome 3 Paroxetine versus newer or non‐conventional ADs.
Comparison 85 SE ‐ Tension, Outcome 1 Paroxetine versus newer or non‐conventional ADs.
Comparison 86 SE ‐ Thirst, Outcome 1 Paroxetine versus newer or non‐conventional ADs.
Comparison 87 SE ‐ Tinnitus, Outcome 1 Paroxetine versus older ADs.
Comparison 87 SE ‐ Tinnitus, Outcome 2 Paroxetine versus newer or non‐conventional ADs.
Comparison 88 SE ‐ Tremor, Outcome 1 Paroxetine versus older ADs.
Comparison 88 SE ‐ Tremor, Outcome 2 Paroxetine versus other SSRIs.
Comparison 88 SE ‐ Tremor, Outcome 3 Paroxetine versus newer or non‐conventional ADs.
Comparison 89 SE ‐ Upper respiratory tract infection, Outcome 1 Paroxetine versus newer or non‐conventional ADs.
Comparison 90 SE ‐ Urination/Urogenital problems, Outcome 1 Difficulty micturating.
Comparison 90 SE ‐ Urination/Urogenital problems, Outcome 2 Dysuria.
Comparison 90 SE ‐ Urination/Urogenital problems, Outcome 3 Urination frequency.
Comparison 90 SE ‐ Urination/Urogenital problems, Outcome 4 Urinary retention.
Comparison 90 SE ‐ Urination/Urogenital problems, Outcome 5 Not Otherwise Specified.
Comparison 91 SE ‐ Visual problems (accommodation disorders, amblyopia, blepharoptosis, blurred vision, detached retina, dry eye, eye strain, mydriasis), Outcome 1 Paroxetine versus older ADs.
Comparison 91 SE ‐ Visual problems (accommodation disorders, amblyopia, blepharoptosis, blurred vision, detached retina, dry eye, eye strain, mydriasis), Outcome 2 Paroxetine versus SSRIs.
Comparison 91 SE ‐ Visual problems (accommodation disorders, amblyopia, blepharoptosis, blurred vision, detached retina, dry eye, eye strain, mydriasis), Outcome 3 Paroxetine versus newer or non‐conventional ADs.
Comparison 92 SE ‐ Vertigo, Outcome 1 Paroxetine versus older ADs.
Comparison 92 SE ‐ Vertigo, Outcome 2 Paroxetine versus other SSRIs.
Comparison 92 SE ‐ Vertigo, Outcome 3 Paroxetine versus newer or non‐conventional ADs.
Comparison 93 SE ‐ Weight gain, Outcome 1 Paroxetine versus older ADs.
Comparison 93 SE ‐ Weight gain, Outcome 2 Paroxetine versus other SSRIs.
Comparison 93 SE ‐ Weight gain, Outcome 3 Paroxetine versus newer or non‐conventional ADs.
Comparison 94 SE ‐ Weight loss, Outcome 1 Paroxetine versus older ADs.
Comparison 94 SE ‐ Weight loss, Outcome 2 Paroxetine versus other SSRIs.
Comparison 94 SE ‐ Weight loss, Outcome 3 Paroxetine versus newer or non‐conventional ADs.
Comparison 95 SE ‐ Yawning, Outcome 1 Paroxetine versus older ADs.
Comparison 95 SE ‐ Yawning, Outcome 2 Paroxetine versus newer or non‐conventional ADs.
Comparison 96 Deaths, suicide and suicidality, Outcome 1 Suicide ‐ attempted.
Comparison 96 Deaths, suicide and suicidality, Outcome 2 Suicide ‐ completed.
Comparison 96 Deaths, suicide and suicidality, Outcome 3 Suicide ‐ tendency/ideation.
Comparison 96 Deaths, suicide and suicidality, Outcome 4 Deaths (any cause).
Update of
References
References to studies included in this review
029060/1/CPMS 069 1991 {unpublished data only}
-
- GlaxomithKline. A multicentre, parallel group study to compare the efficacy and tolerability of paroxetine with clomipramine in elderly patients. www.gsk‐clinicalstudyregister.com 1989.
-
- Rouillon F, et al. A double‐blind, multicentre study comparing increasing doses of paroxetine (20‐50 mg) and clomipramine (50‐150mg) in elderly patients with major depression. World congress of biological psychiatry (poster presentation). 1991.
029060/1/CPMS‐095 {unpublished data only}
-
- GlaxoSmithKline. A double‐blind comparative study of withdrawal effects following abrupt discontinuation of treatment with paroxetine in low or high dose or imipramine. www.gsk‐clinicalstudyregister.com 1992.
0600A‐349 {unpublished data only}
-
- Stahl SM, Entsuah R, Rudolph RL. Comparative efficacy between venlafaxine and SSRIs: A pooled analysis of patients with depression. Biological Psychiatry 2002;52:1166‐74. - PubMed
0600B1‐367 {published data only}
-
- Entsuah R, Shaffer M, Zhang J. A critical examination of the sensitivity of underdimensional subscales derived from the Hamilton Depression Rating Scale to antidepressant drug effects. Journal of Psychiatric Research 2002;36:437‐48. - PubMed
-
- Salinas, Ipr the Venlalaxlne XR 367 Study Group. Wyeth‐AyerstResearch, Paris, France. Once‐dally extended release (XR) venlafaxine versus paroxetlne in outpatients with major depression. Biological psychiatry 1997;42(1):244S.
-
- Shelton C, Entsuah R, Padmanabhan SK, Vinall PE. Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo. Internal Clinical Psychopharmacology 2005;20(4):233‐8. - PubMed
0600B 428 {unpublished data only}
-
- Casabona GM, Silenzi V, Guazzelli M. A randomized, double blind, comparison of venlafaxine ER and paroxetine in outpatients with moderate to severe major depression. European Neuropsychopharmacology 2002;12(Suppl 3):208.
29060/056/UK {unpublished data only}
-
- GlaxoSmithKline. A double‐blind, between patient, multicentre study in general practice comparing the efficacy and tolerability of paroxetine with those of dothiepin in the treatment of elderly depressed patients. www.gsk‐clinicalstudyregister.com.
29060/103 {unpublished data only}
-
- Moon CAL, et al. A double blind, multicentre study comparing the efficacy, tolerability and effects on cognitive function of paroxetine with those of lofepramine in elderly depressed hospital in‐ or out‐patients. British Journal of Clinical Practice 1996.
29060/281 PAR {unpublished data only}
-
- GlaxoSmithKline. A trial to assess the effectiveness and tolerance of paroxetine by double‐blind comparison with amitriptyline in the treatment of depressed patient in General Practice. www.gsk‐clinicalstudyregister.com.
29060/299 {unpublished data only}
-
- GlaxoSmithKline. Double‐blind Study comparing the efficacy and tolerability of paroxetine and amitriptyline in patients with severe depression. www.gsk‐clinicalstudyregister.com.
29060/356 {unpublished data only}
-
- GlaxoSmithKline. A double‐blind, multicentre study to compare paroxetine and fluoxetine in the treatment of patients with major depressive disorder with regard to antidepressant efficacy, effects on associated anxiety and tolerability. www.gsk‐clinicalstudyregister.com 1994.
29060/409 {unpublished data only}
-
- GlaxoSmithKline. A comparative, controlled double blind, double dummy study about the efficacy and safety of paroxetine vs imipramine in ambulatory patients with major depression. www.gsk‐clinicalstudyregister.com.
29060/III/83/022 {unpublished data only}
-
- GlaxoSmithKline. A study to assess the efficacy and tolerance of paroxetine in patients with depression by double‐blind comparison with mianserin. www.gsk‐clinicalstudyregister.com.
29060/III/85/030 {unpublished data only}
-
- GlaxoSmithKline. An assessment of the efficacy and tolerability of paroxetine by double blind comparison with mianserin in patients referred to a psychiatric clinic. www.gsk‐clinicalstudyregister.com.
29060.065.BE {unpublished data only}
-
- Laurelle M, et al. A multicenter double‐blind comparative study between paroxetine and maprolitine in major depression. European Neuropsychopharmacology 1:439 (poster presentation). 1991.
29060.07.001 {unpublished data only}
-
- GlaxoSmithKline. A double‐blind comparison of paroxetine, amitriptyline and placebo in inpatients with major depressive disorder with melancholia. www.gsk‐clinicalstudyregister.com.
29060III/85/038 {unpublished data only}
-
- GlaxoSmithKline. To assess the effectiveness and tolerance of paroxetine in depressed patients by double‐blind comparison with mianserin. www.gsk‐clinicalstudyregister.com.
Aberg‐Wistedt 2000 {published data only}
-
- Aberg‐Wistedt A, Agren H, Ekselius L, Bengtson F, Akerblad AC. Sertraline versus paroxetine in major depression: clinical outcome after six months of continuous therapy. Journal of Clinical Psychopharmacology 2000;20(6):645‐52. - PubMed
-
- Khoury A, Aberg Wistedt A, Stain Malmgren R. Effect of sertraline and paroxetine treatment on depression scores and peripheral indices of serotonergic function in major depression. 11th European College of Neuropsychopharmacology Congress. Paris, France. 31st October 4th November 1998. Utrecht: ECNP, 1998.
-
- Stain‐Malmgren R, Khoury AE, Aberg‐Wistedt A, Tham A. Serotonergic function in major depression and effect of sertraline and paroxetine treatment. International Clinical Psychopharmacology 2001;16(2):93‐101. - PubMed
Ansseau 1993 {published data only}
-
- Ansseau M, Gabriels A, Loyens J, Bartholome F, Evrard J, Nayer A, et al. A double‐blind comparison of paroxetine and fluvoxamine in major depression. European Neuropsychopharmacology 1993;3:323‐4.
-
- Ansseau M, Gabriels A, Loyens J, Bartholome F, Evrard JL, Nayer A, et al. Controlled comparison of paroxetine and fluvoxamine in major depression. Human Psychopharmacology 1994;9:329‐36.
Aoba 2004 {published and unpublished data}
-
- Aoba A, Tanaka Y, Kageyama S, Matsutani S, Mori N, Narita H, et al. A post‐marketing clinical study of Paroxetine hydrochloride hydrate in patients with depression or depressive episodes. A double blind Imipramine hydrochloride controlled comparative study. Japanese Journal of Clinical Psychopharmacology 2004;7(5):831‐53.
Bakish 1997 {published data only}
-
- Bakish D, Cavazzoni P, Chudzik J, Ravindran A, Hrdina PD. Effects of selective serotonin reuptake inhibitors on platelet serotonin parameters in major depressive disorder. Biological Psychiatry 1997;41(2):184‐90. - PubMed
Baldwin 1995 {published data only}
-
- Baldwin D, Hawley CJ, Abed RT, Maragakis BP, Cox J, Buckingham SA, et al. A multicenter double blind comparison of Nefazodone and Paroxetine in the treatment of outpatients with moderate to severe depression. Journal of Clinical Psychiatry 1996;57(Suppl 2):46‐52. - PubMed
Baldwin 2006 {published data only}
-
- Baldwin DS, James AC, Huusom AKT, Hindmarch I. A double blind, randomized, parallel‐group, flexible‐dose study to evaluate the tolerability and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder. International Clinical Psychopharmacology 2006;21:159‐69. - PubMed
Bascara 1989 {published data only}
-
- Bascara B. A double blind study to compare the effectiveness and tolerability of paroxetine and amitriptyline in depressed patients. Acta Psychiatrica Scandinavica, Supplementum 1989;350:141‐2. - PubMed
Battegay 1985 {published data only}
-
- Battegay R, Hager M, Rauchfleisch U. Double‐blind comparative study of paroxetine and amitriptyline in depressed patients of a university psychiatric outpatient clinic. Neuropsychobiology 1985;13:31‐7. - PubMed
Benkert 1999 {published data only}
-
- Benkert O, Szegedi A, Kohnen R. Mirtazapine compared with paroxetine in major depression. Journal of Clinical Psychiatry 2000;61(9):656‐63. - PubMed
Bignamini 1992 {published and unpublished data}
-
- Bignamini A, Rapisarda V. A double‐blind multicentre study of paroxetine and amitriptyline in depressed outpatients. International Clinical Psychopharmacology 1992;6 Suppl 4:37‐41. - PubMed
Blier 2009 {published data only}
-
- Blier P, Gobbi G, Turcotte JE, Montigny C, Boucher N, Hebert C, et al. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination for treatment initiation. European Neuropsychopharmacology 2009;19:457‐65. - PubMed
Boulenger 2006 {published data only}
-
- Boulenger JP, Huusom AKT, Florea I, Baekdal T, Sarchiapone M. A comparative study of the efficacy of long‐term treatment with escitalopram and paroxetine in severely depressed patients. Current Medical Research and Opinion 2006;22(7):1331‐41. - PubMed
Cassano 2002 {published data only}
-
- Cassano GB, Puca F, Scapicchio PL, Trabucchi M. Paroxetine and fluoxetine effects on mood and cognitive functions in depressed nondemented elderly patients. Journal of Clinical Psychiatry 2002;63(5):396‐402. - PubMed
Cassano 2002a {published data only}
-
- Cassano GB, Jori MC. Efficay and safety of amisulpride 50 mg versus paroxetine 20 mg in major depression: a randomized, double‐blind, parallel group study. Internetional Clinical Psychopharmacology 2002;17:27‐32. - PubMed
Chiu 1996 {published data only}
-
- Chiu HJ, Hong CJ, Chan CH. Paroxetine in the treatment of chinese patients with depressive episode: a double blind randomized comparison with Imipramine. Chinese Medical Journal 1996;57:418‐23. - PubMed
Chouinard 1999 {published and unpublished data}
-
- Chouinard G, Saxena B, Belanger MC, Ravindran A, Bakish D, Beauclair L, et al. A Canadian multicenter, double‐blind study of paroxetine and fluoxetine in major depressive disorder. Journal of Affective Disorders 1999;54(1‐2):39‐48. - PubMed
Christiansen 1996 {published data only}
-
- Christiansen PE, Behnke K, Black CH, Ohrstrom JK, Bork‐Rasmussen H, Nilsson J. Paroxetine and amitriptyline in the treatment of depression in general practice. Acta Psychiatrica Scandinavica 1996;93:158‐63. - PubMed
CL3‐023 {published and unpublished data}
-
- European Medicines Agency. Evaluation of Medicines for Human Use: CHMP assessment report for Valdoxan‐Agomelatine. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Public_asses..., Procedure No. EMEA/H/C/000915 2008.
-
- Hickie IB, Rogers NL. Novel melatonin‐based therapies: potential advances in the treatment of major depression. Lancet 2011;378:621‐31. - PubMed
Cohn 1990 {published and unpublished data}
-
- Cohn JB, Crowder JE, Wilcox CS, Ryan PJ. A placebo‐ and imipramine‐controlled study of paroxetine. Psychopharmacology Bulletin 1990;26(2):185‐9. - PubMed
-
- Cohn JB, Wilcox CS. Paroxetine in major depression: a double blind trial with imipramine and placebo. Journal of Clinical Psychiatry 1992;53(2):52‐6. - PubMed
Dalery 2001 {published data only}
-
- Dalery J, Aubin V. Comparative study of Paroxetine and Mianserin in depression of the elderly: efficacy, tolerance, serotonine dependance. L'Encephale 2001;27:71‐81. - PubMed
Davidson 2005 {published data only}
-
- Davidson J, Watkins L, Owens M, Krulewicz S, Connor K, Carpenter D, et al. Effects of Paroxetine and Venlafaxine XR on heart rate variability in depression. Journal of Clinical Psychopharmacology 2005;25(5):480‐4. - PubMed
Demyttenaere 2002 {published data only}
-
- Demyttenaere K, Albert A, Mesters P, Dewe W, Bruyckere K, Sangeleer M. What happens with adverse events during 6 months of treatment with selective serotonin reuptake inhibitors?. Journal of Clinical Psychiatry 2005;66(7):859‐63. - PubMed
-
- Demyttenaere K, Bruffaerts R, Albert A, Mesters P, Dewe W, Debruyckere K, Sangeleer M. Development of an antidepressant compliance questionnaire. Acta Psychiatrica Scandinavica 2004;110(3):201‐7. - PubMed
-
- Demyttenaere K, Mesters P, Dewe W, Boulanger B, Bruyckere K, Sangeleer M, et al. Six month compliance with fluoxetine or paroxetine treatment in depressed outpatients. European Neuropsychopharmacology 2002;12(Suppl 3):208.
Detke 2004 (HMAY A) {published and unpublished data}
-
- Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I. Duloxetine in the acute and long‐term treatment of major depressive disorder: a placebo‐ and paroxetine‐controlled trial. European Neuropsychopharmacology 2004;14(6):457‐70. - PubMed
De Wilde 1993 {published data only}
-
- Wilde J, Spiers R, Mertens C, Bartholome F, Schotte G, Leyman S. A double‐blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients. Acta Psychiatrica Scandinavica 1993;87(2):141‐5. - PubMed
Dichter 2005 {published data only}
-
- Dichter GS, Tomarken AJ, Freid CM, Addington S, Shelton RC. Do venlafaxine XR and paroxetine equally influence negative and positive affect?. Journal of Affective Disorders 2005;85(3):333‐9. - PubMed
Dorman 1992 {published data only}
-
- Dorman T. Sleep and paroxetine: a comparison with mianserin in elderly depressed patients. International Clinical Psychopharmacology 1992;6(4):53‐8. - PubMed
DUAG 1990 {published data only}
-
- Danish University Antidepressant Group. Paroxetine: A selective serotonine reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Journal of Affective Disorder 1990;18:289‐99. - PubMed
Dunbar 1991 {published and unpublished data}
-
- Dunbar GC, Cohn JB, Fabre LF, Feighner JP, Fieve RR, Mendels, et al. A comparison of paroxetine, imipramine and placebo in depressed outpatients. British Journal of Psychiatry 1991;159:394‐8. - PubMed
-
- Lapierre Y, Bentkover J, Schainbaum S, Manners S. Direct cost of depression: analysis of treatment costs of paroxetine versus Imipramine in Canada. Canadian Journal of Psychiatry 1995;40(7):370‐7. - PubMed
Dunner 1992 {published and unpublished data}
-
- Dunner DL, Cohn J, Walshe T, Cohn CK, Feighner JP, Fieve RR, et al. Two combined, multicenter double‐blind studies of Paroxetine and Doxepin in geriatric patients with major depression. Journal of Clinical Psychiatry 1992;53(2):57‐60. - PubMed
Fabre 1992 {published and unpublished data}
-
- Fabre LF. A 6‐week, double‐blind trial of paroxetine, imipramine and placebo in depressed outpatients. Clinical Journal of Psychiatry 1992;53(2):40‐3. - PubMed
Fava 1998 {published data only}
-
- Fava M, Amsterdam JD, Deltito JA, Salzman C, Schwaller M, Dunner DL. A double‐blind study of paroxetine, fluoxetine, and placebo in outpatients with major depression. Annals of Clinical Psychiatry 1998;10(4):145‐50. - PubMed
Fava 2002 {published data only}
-
- Fava M, Hoog SL, Judge RA, Kopp JB, Nilsson ME, Gonzales JS. Acute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline insomnia. Journal of Clinical Psychopharmacology 2002;22(2):137‐47. - PubMed
-
- Fava M, Judge R, Hoog SL, Nilsson ME, Koke SC. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long‐term treatment. Journal of Clinical Psychiatry 2000;61(11):863‐7. - PubMed
-
- Fava M, Rosenbaum JF, Hoog SL, Tepner RG, Kopp JB, Nilsson ME. Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression. Journal of Affective Disorders 2000;59(2):119‐26. - PubMed
Feighner 1989 {published and unpublished data}
-
- Feighner JP, Boyer WF. Paroxetine in the treatment of depression: a comparison with imipramne and placebo. Acta Psychiatrica Scandinavica 1989;80(350):125‐9. - PubMed
Freed 1996 {published and unpublished data}
-
- Freed E, George T, Goldney R, Lambert T, Tiller J. A double‐blind multicentre comparison of paroxetine and amitriptyline in Australian general‐practice. XXth Collegium Internationale Neuro psychopharmacologicum, Melbourne, Australia. 1996.
-
- Freed E, Goldney R, Lambert T, Tiller J, Johnston R. A double‐blind, multicentre study to assess the tolerability and efficacy of paroxetine compared with amitriptyline in the treatment of depressed patients in Australian general practice. Australian and New Zealand Journal of Psychiatry 1999;33:416‐21. - PubMed
Gagiano 1993 {published and unpublished data}
-
- Gagiano CA. A double blind comparison of paroxetine and fluoxetine in patients with major depression. British Journal of Clinical Research 1993;4:145‐52.
-
- Gagiano CA, Judge R. Paroxetine vs. fluoxetine. Clinical Neuropharmacology 1992;15(1):334.
Gallen 2001 {published data only}
-
- Brown MT, Brinkman SA, Reisner JK, Rowland CR. Reboxetine, placebo, and paroxetine comparison in patients with major depressive disorder. Clinical Research. Pharmacia & Upjoh 2001.
-
- Ferguson J, Wesnes K, Barker K, Schwartz G. Reboxetine effects on cognitive functioning in depressed patients. European Neuropsychopharmacology 2002;12(Suppl 3):206.
-
- Ferguson JM, Wesnes KA, Schwartz GE. Reboxetine effects on cognitive functioning in depressed patients. 155th Annual Meeting of the American Psychiatric Association, Philadelphia, PA. 2002.
-
- Ferguson JM, Wesnes KA, Schwartz GE. Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients. International Clinical Psychopharmacology 2003;18(1):9‐14. - PubMed
-
- Gallen CC, Brown MT. Reboxetine versus paroxetine versus placebo in patients with major depressive disorder. European Neuropsycopharmacology. 2001; Vol. 11, issue suppl3:S216.
Geretsegger 1994 {published and unpublished data}
-
- Geretsegger C, Bohmer F, Ludwig M. Paroxetine in the elderly depressed patient: randomized comparison with fluoxetine of efficacy, cognitive and behavioural. International Clinical Psychopharmacology 1994;9:25‐9. - PubMed
-
- Schone W, Ludwig M. A double‐blind study of paroxetine compared with fluoxetine in geriatric patients with major depression. Journal of Clinical Psychopharmacology 1993;13:34‐9. - PubMed
-
- Schone W, Ludwig M. Paroxetine in the treatment of depression in geriatric patientsa double‐blind comparative study with fluoxetine. Fortschritte der Neurologie Psychiatrie 1994;62(Suppl1):16‐8. - PubMed
Geretsegger 1995 {published and unpublished data}
-
- Geretsegger C, Stuppaeck CH, Mair M, Platz T, Fartacek R, Heim M. Multicentre double‐blind study of paroxetine and amitriptyline in elderly depressed inpatients. Psychopharmacology 1995;119:277‐81. - PubMed
Gilmor 2002 {published data only}
-
- Gilmor ML, Owens MJ, Nemeroff CB. Inhibition of Norepinephrine uptake in patients with major depression treated with Paroxetine. American Journal of Psychiatry 2002;159(10):1702‐10. - PubMed
Goldstein 2004 (HMAT B) {published and unpublished data}
-
- Goldstein DJ, Lu Y, Dekte MJ, Wiltse CG, Mallinckrodt C, Demitrack MA. Duloxetine versus Paroxetine in the treatment of depression. 155th Annual Meeting of American Psychiatric Association. 2002 May 18‐23; Philadelphia.
-
- Goldstein DJ, Lu Y, Detke M, Wiltse C, Mallinckrodt C, Demitrack MA. Duloxetine in the treatment of depression: a double blind placebo controlled comparison with Paroxetine. European Neuropsychopharmacology 2002;12:43‐4. - PubMed
-
- Goldstein DJ, Lu Y, Detke MJ, Wiltse C, Mallinckrodt C, Demitrack MA. Duloxetine in the treatment of depression: a double‐blind placebo‐controlled comparison with paroxetine. Journal of Clinical Psychopharmacology 2004;24(4):389‐99. - PubMed
-
- Mallinckrodt C, Goldstein DJ, Lu Y, Detke M, Wiltse C, Demitrack MA. Duloxetine in the treatment of depression: a double blind placebo controlled comparison with Paroxetine. European Neuropsychopharmacology 2002;12(Suppl 3):S214. - PubMed
Guillibert 1989 {published data only}
-
- Guillibert E, Pelicier Y, Archambault JC, Chabannes JP, Clerc G, Desvilles M, et al. A double blind, multicentre study of Paroxetine versus Clomipramine in depressed elderly patients. Acta Psychiatrica Scandinavica 1989;80(Suppl 350):132‐4. - PubMed
Hicks 2002 {published data only}
-
- Argyropuolos SV, Hicks JA, Nash JR, Bell CJ, Rich AS, Nutt DJ, et al. Correlation of subjective and objective sleep measurements at different statges of the treatment of depression. Psychiatry Research 2003;120:179‐90. - PubMed
-
- Hicks JA, Argyropoulos SB, Rich AS, Nash JR, Bell CJ, Edwards C, et al. Randomized controlled study of sleep after Nefazodone or Paroxetine treatment in outpatients with depression. British Journal of Psychiatry 2002;180:528‐35. - PubMed
Higuchi 2009 {published data only}
-
- Higuchi T, Murasaki M, Kamijima K. Clinical evaluation of duloxetine in the treatment of major depressive disorder placebo and paroxetine controlled double‐blind comparative study. Japanese Journal of Clinical Psychopharmacology 2009;12:1613‐34.
HMAT A (ID#4091) {unpublished data only}
-
- Eli Lilly. Duloxetine versus placebo and paroxetine in the acue treatment of major depression, study group a. www.lillytrials.com www.clinicalstudyresults.org.
-
- Eli Lilly and company (www.clinicalstudyresults.org). Duloxetine versus placebo and paroxetine in the acute treatment of major depression, Study group A. www.clinicalstudyresults.org 2004.
Hutchinson 1992 {published data only}
-
- Hutchinson DR, Tong S, Moon CA, Vince M, Clarke A. Paroxetine in the treatment of elderly depressed patients in general practice: a double‐blind comparison with amitriptyline. International Clinical Psychopharmacolology 1992;6(4):43‐51. - PubMed
-
- Hutchinson DR, Tong S, Moon CAL, Vince M, Clarke A. A double blind study in general practice to compare the efficacy and tolerability of paroxetine and amitriptyline in depressed elderly patients. British Journal of Clinical Research 1991;2:43‐57.
Hwang 2004 {published data only}
-
- Hwang J‐P, Yang C‐H, Tsai S‐J. Comparison study of venlafaxine and paroxetine for the treatment of depression in elderly Chinese inpatients. Internationa Journal of Geriatric Psychiatry 2004;19:189‐90. - PubMed
Javors 2000 {published data only}
-
- Javors MA, Houston JP, Tekell JL, Brannan SK, Frazen A. Reduction of platelet serotonin content in depressed patients treated with either paroxetine or desipramine. International Journal of Neuropsychopharmacology 2000;3:229‐35. - PubMed
Jefferson 2001 29060/785 {unpublished data only}
-
- Jefferson JW, Griest J. A double blind comparison of citalopram and paroxetine in the treatment of patients with depression and anxiety. 39th Annual Meeting of the American College of Neuropsychopharmacology. 2000, Dec 10‐14; San Juan; Puerto Rico.
-
- Jefferson JW, Griest J. Citalopram compared with paroxetine in depressed patients with associated anxiety. 154th Annual Meeting of the American Psychiatric Association; New Orleans; LA. 2001 May 5‐10.
Kasper 2005 {published data only}
-
- Kasper S, Olivieri L, loreto G, Dionisio P. A comparative, randomised, double‐blind study of trazodone prolonged‐release and paroxetine in the treatment of patients with major depressive disorder. Current Medical Research and Opinion 2005;21(8):1139‐46. - PubMed
Kato 2005 {published data only}
-
- Kato M, Ikenaga Y, Wakeno M, Okugawa G, Nobuhara K, Fukuda T, et al. Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism. International Clinical Psychopharmacology 2005;20:151‐56. - PubMed
-
- Kato M, Ikenaga Y, Wakeno M, Okugawa G, Nobuhara K, Fukuda T, et al. Effects of the serotonin type 2A, 3A and 3B receptor and the serotonintransporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed japanese patients. Neuropsychobiology 2006;53:186‐95. - PubMed
-
- Kato M, Wakeno M, Okugawa G, Nagata M, Nobuhara K, Ochi T, et al. Clinical comparison of paroxetine and fluvoxamine considering of the serotonin transporter promoter polymorphism in patients with affective disorder. International Clinical Psychopharmacology 2004;19(3):175. - PubMed
Katz 2004 {published data only}
-
- Katz MM, Tekell JL, Bowden CL, Brannan S, Houston JP, Berman N, et al. Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression. Neuropsychopharmacology 2004;29:566‐79. - PubMed
Kennedy 2004 {published and unpublished data}
-
- GlaxoSmithKline. An eight‐week doubleblind study comparing the effects of 20 mg of paroxetine to 150 mg Wellbutrin SR in patients with Major Depressive Disorder. www.gsk‐clinicalstudyregistrer.com.
-
- Kennedy SH. Differences in sexual disfunction between men and women with depression: a comparison before and after treatment with bupropion and paroxetine. Neuropsycophamacology 2004;29(Suppl1):S148‐9.
-
- Kennedy SH, Fulton KA, Bagby M, Greene A, Cohen NL, Shahryar RT. Sexual function during bupropion or paroxetine treatment of major depressive disorder. Canadian Journal of Psychiatry 2006;51(4):234‐42. - PubMed
Kiev 1997 {published and unpublished data}
-
- Kiev A, Feiger A. A double‐blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients. Journal of Clinical Psychiatry 1997;58(4):146‐52. - PubMed
-
- Kiev A, Feiger A. Comparison of fluvoxamine and paroxetine in depression. Xth World Congress of Psychiatry. Madrid, Spain, 1996.
-
- Kiev A, Feiger AD. A double‐blind comparison of fluvoxamine and paroxetine in major depressive disorder. 149th Annual Meeting of the American Psychiatric Association. New York, NY, 1996.
Kramer 1998 {published data only}
-
- Feighner JP. Substance P. 11th European College of Neuropsychopharmacology Congress. Paris, France. 1998.
-
- Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ, et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998;281:1640‐5. - PubMed
Kramer 2001 {published data only}
-
- Kramer MS. Substance P (NKI) receptor antagonists (SPAs) in patients with major depression. 40th Annual Meeting, American College of Neuropsychopharmacology, Waikoloa, HI. 2001.
-
- Krishnan RR. Clinical experience with substance p receptor (nk1) antagonists in depression. Journal of Clinical Psychiatry 2002;63(Suppl 11):25‐9. - PubMed
Kuhs 1989 {published and unpublished data}
-
- Khus H, et al. A double‐blind study of paroxetine versus amitriptyline, with particular reference to cardiovascular effects. Proceedings of the World Congress of Biological Psychiatry. 1991:22‐23 (poster presentation).
-
- Kuhs H, Rudolf GA. A double‐blind study of the comparative antidepressant effect of paroxetine and amitriptyline. Acta Psychiatrica Scandinavica 1989;80(350):145‐6. - PubMed
-
- Kuhs H, Rudolf GA. Cardiovascular effects of paroxetine. Psychopharmacology 1990;102(3):379‐82. - PubMed
-
- Kuhs H, Rudolf GA, Schlake HP, Rolf LH. Relationship between parameters of serotonin transport and antidepressant plasma levels or therapeutic response in depressive patients treated with paroxetine and amitriptyline. Acta Psychiatrica Scandinavica 1992;85(5):364‐9. - PubMed
Laghrissi‐Thode 1995 {published data only}
-
- Laghrissi‐Thode F, Pollock BG, Miller MC, Mulsant BH, Altieri L, Finkel MS. Double‐blind comparison of paroxetine and nortriptyline on the postural stability of late‐life depressed patients. Psychopharmacology Bulletin 1995;31(4):659‐63. - PubMed
Laursen 1985 {published and unpublished data}
-
- Laursen AL, Mikkelsen PL, Fievre Honore P. Paroxetine in the treatment of depression ‐ a randomised comparison with amitriptyline. Acta Psychiatrica Scandinavica 1985;71:249‐55. - PubMed
Lee 2007 (HMCV) {published data only}
-
- Lee P, Shu L, Xu X, Wang CY, Lee MS, Liu CY, et al. Once‐daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double‐blind, randomized, paroxetine‐controlled, non‐inferiority trial in China, Korea, Taiwan and Brazil. Psychiatry and Clinical Neurosciences 2007;61(3):295‐307. - PubMed
Lepine 2001 {published data only}
-
- Lepine JP, Altamura C, Ansseau M, Ayuso Gutierrez JL, Bitter I, Lader M, et al. Tienapine and paroxetine in major depressive disorder, with a special focus on the anxious component in depression: an international, 6 week double‐blind study. Human Psychopharmacology: Clinical and Experimental 2001;16(3):219‐27. - PubMed
Loo 2002 {published data only}
-
- Loo H, Hale A, D'haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5‐HT antagonist, in the treatment of major depressive disorder: a placebo‐controlled dose range study. International Clinical Psychopharmacology 2002;17:239‐47. - PubMed
M/2020/0047 {unpublished data only}
-
- Brown MT, Brinkman SA, Reisner JK, Rowland CR. Reboxetine, placebo, and paroxetine comparison in patients with major depressive disorder. Clinical Research. Pharmacia & Upjohn; 6/2/2001.
M/2020/0052 {unpublished data only}
-
- Baldwin D, Bridgman K, Buis C. Resolution of sexual dysfunction during double‐blind treatment of major depression with reboxetine or paroxetine. Journal of Psychopharmacology 2006;20(1):91‐6. - PubMed
-
- Linde AS, Bartlett C, Math M, Richard KA. Reboxetine (PNU‐1555950E) vs Paroxetine in a double‐blind, multinational study of treatment in major depressive disorder. Clinical Research. Pharmacia & Upjohn 9/9/2004.
Mc Partlin 1998 {published data only}
-
- McPartlin GM, Reynolds A, Anderson C, Casoy J. A comparison of once‐daily venlafaxine XR and paroxetine in depressed out patients treated in general practice. Primary Care Psychiatry 1998;4:127‐32.
Montgomery 2004 {published data only}
-
- Montgomery SA, Kennedy SH, Burrows GD, Lejoyeux M, Hindmarch I. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double‐blind, placebo‐controlled discontinuation study. International Clinical Psychopharmacology 2004;19(5):271‐80. - PubMed
Moon 1996 {published and unpublished data}
-
- Moon C, Vince M. Treatment of major depression in general practice: a double‐blind comparison of paroxetine and lofepramine. British Journal of Clinical Practice August 1996;50(5):240‐4. - PubMed
Mulsant 1999 {published data only}
-
- Fabian TJ, Dew MA, Pollock BG, Reynolds CF, Mulsant BH, Butters MA, et al. Endogenous concentrations of DHEA and DHEA‐S. Decrease with remission of depression in older adults. Biological Psychiatry 2001;50(10):767‐74. - PubMed
-
- Fabian TJ, Kroboth PD, Butters MA, et al. Are DHEA and/or DHEA‐S concentrations associated with remission of depression or improvements in mental status scores in older adults. 12th Annual Meeting of the American Association for Geriatric Psychiatry, New Orleans LA. 1999.
-
- Mulsant BH, Pollock BG, Nebes RD, Miller MD, Little JT, Stack J, et al. A double‐blind randomized comparison of nortriptyline and paroxetine in the treatment of late‐life depression: 6‐week outcome. Journal of Clinical Psychiatry 1999;60(Suppl 20):16‐20. - PubMed
MY‐1045/BRL‐029060/1 {unpublished data only}
-
- GlaxoSmithKline. A multicenter, randomized, double‐blind, placebo‐controlled comparison of paroxetine and fluoxetine in the treatment of major depressive disorder. www.gsk‐clinicalstudyregister.com.
NCT00463242 {published and unpublished data}
-
- European Medicines Agency. Evaluation of Medicines for Human Use: CHMP assessment report for Valdoxan‐Agomelatine. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Public_asses..., Procedure No. EMEA/H/C/000915 2008.
-
- Hickie IB, Rogers NL. Novel melatonin‐based therapies: potential advances in the treatment of major depression. Lancet 2011;378:621‐31. - PubMed
Nickel 2003 {published data only}
-
- Nickel T, Sonntag A, Schill J, Zobel AW, Nibal A, Brunnauer A, et al. Clinical and neurobiological effects of tianeptine and paroxetine in major depression. Journal of Clinical Psychopharmacology 2003;23:155‐168. - PubMed
Nielsen 1991 {published data only}
-
- Nielsen OA, Morsing I, Petersen JS, Larsen T, Moller SE, Manniche PM, et al. Paroxetine and imipramine treatment of depressive patients, in a controlled multicentre study with plasma amino acid measurements. Acta Psychiatrica Scandinavica 1991;84:233‐41. - PubMed
-
- Skausig OB, Nielsen OA, Morsing I, Petersen JS, Larsen T, Moller SE, et al. Paroxetine and imipramine treatment of depressed patients in a controlled, multicentre study with plasma amino acid measurements. Nordic Journal of Psychiatry 1992;46(Suppl 27):23‐6.
Ohrberg 1992 {published and unpublished data}
-
- Chiristainsen PE. Paroxetine and imipramine in the treatment of depressed patients in psychiatric specialist practice. Nordic Journal of Psychiatry 1992;27:33‐9.
-
- Ohrberg S, Christainsen PE, Severin B, Calberg H, Nilakantan B, Borup A, et al. Paroxetine and imipramine in the treatment of depressive patients in psychiatric practice. Acta Psychiatrica Scandinavica 1992;86:437‐44. - PubMed
Ontiveros 1994 {published and unpublished data}
-
- Garcia Barriga, et al. A double‐blind study with paroxetine vs fluoxetine in depressive patients. Xth World Congress of Psychiatry, Madrid, Spain. 1996.
-
- Ontiveros A, et al. A double blind study with paroxetine vs fluoxetine in depressive patients. Biological Psychiatry 1994;35:677.
Owens 2008 {published data only}
-
- Owens MJ, Krulewicz S, Simon JS, Sheehan DV, Thase ME, Carpenter DJ, et al. Estimates of serotonin and norepinephrine transporter inhibition in depressed patients treated with paroxetine or venlafaxine. Neuropsychopharmacology 2008;33:3201‐12. - PubMed
PAR MDUK 032 {unpublished data only}
-
- GlaxoSmithKline. A double ‐blind study to compare the efficacy and tolerability of paroxetine and amitriptyline in a multicentre general practice study in depressed patients. www.gsk‐clinicalstudyregister.com.
Pelicier 1993 {published and unpublished data}
-
- Pelicier Y, Schaeffer P. A multicentre, double‐blind study to compare the efficacy and tolerability of paroxetine and clomipramine in elderly patients with reactive depression. Acta Psychiatrica Scandinavica 1989;80:132. - PubMed
-
- Pelicier Y, Schaeffer P. A multicentre, double‐blind study to compare the efficacy and tolerability of paroxetine and clomipramine in elderly patients with reactive depression [Etude multicentrique en double aveugle comparant l'efficacité et la tolérance de la paroxétine et de la clomipramine dans la dépression réactionnelle du suject agé]. L'Encephale 1993;19:257‐61. - PubMed
Perahia 2006 (HMAY B) {published and unpublished data}
-
- Eli Lilly, company. Clinical study summary ID#4298. www.lilly.com 2006.
-
- Perahia DG, Wang F, Mallinckrodt CH, Walker DJ, Detke MJ. Duloxetine in the treatment of major depressive disorder: a placebo‐ and paroxetine‐controlled trial. European Psychiatry 2006;21(6):367‐78. - PubMed
Peselow 1989 {published and unpublished data}
-
- Dunbar GC, Cohn JB, Fabre LF, Feighner JP, Fieve RR, Mendels J, et al. A comparison of paroxetine, imipramine and placebo in depressed out‐patients. British Journal of Psychiatry 1991;159:394‐8. - PubMed
-
- Feighner JP, Cohn JB, Fabre LF Jr, Fieve RR, Mendels J, Shrivastava RK, et al. A study comparing Paroxetine placebo and imipramine in depressed patients. Journal of Affective Disorders 1993;28(2):71‐9. - PubMed
-
- Peselow ED, Filippi AM, Goodnick P, Barouche F, Fieve RR. A double‐blind, Imipramine‐ and placebo‐controlled study of paroxetine in depressed outpatients. Psychopharmacology Bulletin 1989;25(2):272‐6. - PubMed
Ravindran 1997 {published and unpublished data}
-
- Hunter B. A double‐blind multicentre study in primary care comparing paroxetine and clomipramine in patients with depression with associated anxiety. European College of Neuropsychopharmacology Congress (ECNP), Venice. 1995. - PubMed
-
- Ravindran AV, et al. A double‐blind, multicenter study in primary care comparing paroxetine and clomipramine in subjects with depression and associated anxiety. Journal of Clinical Psychiatry 1997;58:112‐8. - PubMed
Sacchetti 2002 {published and unpublished data}
-
- Sacchetti E, Cassano GB, Penati G, Pavan L, Nardini M, Casacchia M, et al. Paroxetine versus amitriptyline in patients with recurrent major depression: a double‐blind trial. International Journal of Psychiatry in Clinical Practice 2002;6:23‐9. - PubMed
SBK‐115 1998 {unpublished data only}
-
- GlaxoSmithKline. A multicenter, randomized, double‐blind, placebo‐controlled comparison of paroxetine and fluoxetine in the treatment of major depressive disorder. www.gsk‐clinicalstudyregister.com.
Schatzberg 2002 {published data only}
-
- Schatzberg AF, Kremer C, Rodrigues HE, Murphy GM Jr, Mirtazapine vs. Paroxetine Study Group. Double‐blind randomized comparison of mirtazapine and paroxetine in elderly depressed patients. American Journal of Geriatric Psychiatry September‐October 2002;10(5):541‐50. - PubMed
Schnyder 1996 {published data only}
-
- Schnyder U. Sudden recovery from depression under treatment with paroxetine. European Journal of Psychiatry 1996;10(3):184‐7.
-
- Schnyder U, Koller‐Leiser A. A double‐blind, multicentre study of paroxetine and maprolitine in major depression. Canadian Journal of Psychiatry 1996;41:239‐44. - PubMed
Sechter 2004 {published data only}
-
- Sechter D, Vandel P, Weiller E, Pezous N, Cabanac F, Tournoux. A comparative study of milnacipran and paroxetine in outpatients with major depression. Journal of Affective Disorders 2004;83:233‐6. - PubMed
-
- Vandel P, Sechter D, Weiller E, Pezous N, Cabanac F, Tournoux A, et al. Post‐treatment emergent adverse events in depressed patients following treatment with milnacipran and paroxetine. Human Psychopharmacololy 2004;19:585‐6. - PubMed
SER‐CHN‐1 {unpublished data only}
-
- GlaxoSmithKline. Antidepressant efficacy and safety of paroxetine; a double blind amitriptyline controlled multicenter comparison study in depressive patients. www.gsk‐clinicalstudyregister.com 1994.
Shillingford 1990 {unpublished data only}
-
- Shillingford JS, Shrivastava SH, Overweg N, Blumhardt CL. A double‐blind comparison of paroxetine and dothiepin on efficacy and tolerability in depressed community patients. Collegium Internationale Neuropsychopharmacologium Congress, Kyoto, Japan 1990.
Shinkai 2004 {published data only}
-
- Shinkai K, Yoshimura R, Ueda N, Okamoto K, Nakamura J. Associations between baseline plasma MHPG (3‐methoxy‐4‐hydroxyphenylglycol) levels and clinical responses with respect to milnacipran versus paroxetine treatment. Journal of Clinical Psychopharmacology 2004;24(1):11‐7. - PubMed
Shrivastava 1992 {published and unpublished data}
-
- Shrivastava RK, Shrivastava P, Overweg N, Blumhardt C. A double blind comparison of Paroxetine, Imipramine and placebo in Major Depression. Journal of Clinical Psychiatry 1992;53(2 (Suppl)):48‐51. - PubMed
Staner 1995 {published data only}
-
- Staner L, Kerkhofs M, Detroux D, Leyman S, Linkowski P, Mendlewicz J. Acute, subchronic and withdrawal sleep EEG changes during treatment with paroxetine and amitriptyline: a double‐blind randomized trial in major depression. Sleep 1995;18:470‐7. - PubMed
Steinmeyer 1992 {published data only}
-
- Moller HJ, Berzewski H, Eckmann F, Gonzalves N, Kissling W, Knorr W, et al. Double‐blind multicenter study of paroxetine and amitriptyline in depressed patients. Pharmacopsychiatry 1993;26:75‐8. - PubMed
-
- Moller HJ, Steinmeyer EM. Are serotonergic reuptake inhibitors more potent in reducing suicidality? An empirical study on paroxetine. Eurpean Neuropsychopharmacology 1994;4:55‐9. - PubMed
Stott 1993 {published data only}
-
- Stott PC, Blagden MD, Aitken CA. Depression and associated anxiety in primary care: a double‐blind comparison of paroxetine and amitriptyline. European Neuropsychopharmacology 1993;3:324‐5.
Stuppaeck 1994 {published data only}
-
- Stuppaeck CH, Geretsegger C, Whitworth AB, Schubert H, Platz T, Konig P, et al. A multicentre double‐blind trial of paroxetine versus amitriptyline in depressed inpatients. Journal Clinical Psychopharmacology 1994;14:241‐6. - PubMed
Szegedi 1995 {published and unpublished data}
-
- Szegedi A, Wetzel H, Angersbach D, Philipp M, Benkert O. Response to treatment in minor and major depression: results of a double‐blind comparative study with paroxetine and maprotiline. Journal of Affective Disorders 1997;45:167‐78. - PubMed
-
- Szegedi A, Wetzel H, Angersbach D, Philipp M, Benkert O, Dunbar GC, et al. A double‐blind study comparing paroxetine and maprotiline in depressed outpatients. Pharmacopsychiatry 1997;30:97‐105. - PubMed
Szegedi 2005 {published data only}
Tignol 1993 {published and unpublished data}
-
- Tignol J. A double‐blind, randomised, multicentre study comparing paroxetine 20mg daily versus fluoxetine 20mg daily in the treatment of adults with major depression. Clinical Neuropharmacology 1992;15:177.
-
- Tignol J. Double‐blind, randomized, fluoxetine‐controlled multicenter study of paroxetine in the treatment of depression. Journal of Clinical Psychopharmacology 1993;6(2):18S‐22S. - PubMed
-
- Tignol J, et al. A double blind, randomized, multicentre study comparing paroxetine 20 mg daily in te treatment of adults with major depression with regard to antidepressant efficacy, tolerance and anxiolytic effect [Etude multicentrique randomisee, en duoble aveugle comparant la paroxetine 20mg a fluoxetine 20mg chez des patients depressif hopitalises]. Acta med Int Psychiatr 1994;12:2558‐62.
Wade 2003 {published data only}
-
- Wade A, Crawford GM, Angus M, Wilson R Hamilton L. A randomized, double‐blind, 24‐week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care. International Clinical Psychopharmacology 2003;18:133‐41. - PubMed
Waintraub 2002 {published data only}
-
- Waintraub L, Septien L, Azoulay P. Efficacy and safety of tianeptine in major depression. CNS Drugs 2002;16(1):65‐75. - PubMed
Weihs 2000 {published and unpublished data}
-
- Weihs KL, Settle EC Jr, Batley SR, Houser TL, Donahue RM, Ascher JA. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. Journal of Clinical Psychiatry 2000;61:196‐202. - PubMed
Yoshimura 2007 {published data only}
-
- Yoshimura R, Mitoma M, Sugita A, Hori H, Okamoto T, Umene W, et al. Effects of paroxetine or milnacipran on serum brain‐derived neurotrophic factor in depressed patients. Progress in Neuro‐Psychopharmacology and Biological Psychiatry 2007;31(5):1034‐7. - PubMed
References to studies excluded from this review
Arminen 1992 {published data only}
-
- Arminem S‐L, Ikonen U, Pulkkinen M, Leinonen E, Mahlanen A, Koponen H, et al. Paroxetine and imipramine:a 12‐week, double blind, multicentre study in hospitalized depressed patient. Nordic Journal of Psichiatry 1992;46, Suppl. 27:27‐31.
-
- Arminen SL, Ikonen U, Pulkkinen P, Leinonen E, Mahlanen A, Koponen H, et al. A 12‐week double‐blind multi‐centre study of paroxetine and imipramine in hospitalized depressed patients. Acta Psychiatrica Scandinavica 1994;89(6):382‐9. - PubMed
Benkert 1997 {published data only}
-
- Benkert O, Szegedi A, Wetzel H, Staab HJ, Meister W, Philipp M. Dose escalation vs continued doses of paroxetine and maprotiline: a prospective study in depressed out‐patients with inadequate treatment response. Acta Psychiatrica Scandinavica 1997;95(4):288‐96. - PubMed
Bird 2000 {published data only}
-
- Bird H, Broggini M. Paroxetine versus amitriptyline for treatment of depression associated with rheumatoid arthritis: A randomized, double blind, parallel group study. Journal of Rheumatology 2000;27(12):2791‐7. - PubMed
Cocchi 1997 {published data only}
-
- Cocchi R. Paroxetine vs amitryptiline in depressed alcoholics. 10th European College of Neuropsychopharmacology Congress. Vienna, Austria. 1997.
Ferrando 1997 {published data only}
-
- Ferrando SJ, Goldman JD, Charness WE. Selective serotonin reuptake inhibitor treatment of depression in symptomatic HIV infection and AIDS: Improvements in affective and somatic symptoms. General Hospital Psychiatry 1997;19(2):89‐97. - PubMed
Gulseren 2005 {published data only}
-
- Gulseren L, Gulseren S, Hekimsoy Z, Mete L. Comparison of fluoxetine and paroxetine in type II diabetes mellitus patients. Archives of Medical Research 2005;36(2):159‐65. - PubMed
Hazleman 1997 {published data only}
-
- Hazleman BL. A double blind, multicentre study to assess the efficacy and tolerability of paroxetine and amitriptyline in patients with a mild, moderate or severe depressive episode associated with rheumatoid arthritis. National Research Register 1997.
Katona 1998 {published data only}
-
- Katona C, Hunter B, Judge R. A double‐blind comparison of the efficacy and safety of paroxetine and imipramine in the treatment of depression with dementia. Xth World Congress of Psychiatry, Madrid, Spain. 1996. - PubMed
-
- Katona CL, Hunter BN, Bray J. A double‐blind comparison of the efficacy and safely of paroxetine and imipramine in the treatment of depression with dementia. International Journal of Geriatric Psychiatry 1998;13(2):100‐8. - PubMed
Poirier 1997 {published data only}
-
- Poirier MF. The concept of resistant depression and therapeutic strategies, particularly with venlafaxine. L'Encephale 1999;25(2):55‐7. - PubMed
-
- Poirier MF. Venlafaxine versus paroxetine in the treatment of resistant depression. Sixth World Congress of Biological Psychiatry, Nice, France. 1997.
-
- Poirier MF, Boyer P. Venlafaxine and paroxetine in treatment‐resistant depression. Double‐ blind, randomised comparison. British Journal of Psychiatry 1999;174:12‐6. - PubMed
-
- Poirier MF, Boyer P. Venlafaxine versus paroxetine for treatment resistant depression. XXIst Collegium Internationale Neuro psychopharmacologicum, Glasgow, Scotland. 12th 16th July, 1998.
-
- Schaeffer P, Poirier FM, Boyer P. Double‐blind trial of venlafaxine and paroxetine for treatment‐resistant depression. 11th European College of Neuropsychopharmacology Congress. Paris, France. 1998.
Rapaport 2003 {published data only}
-
- Rapaport MH, Schneider LS, Dunner DL, Davies JT, Pitts CD. Efficacy of controlled‐release paroxetine in the treatment of late‐life depression. Journal of Clinical Psychiatry 2003;64(9):1065‐74. - PubMed
Sacchetti 1997 {published data only}
-
- Sacchetti E, Conte G, Guarneri L, Calzeroni A, Bertini M, Panariello A. Effectiveness of fluvoxamine and paroxetine in major depressives with psychotic features. Human Psychopharmacology 1997;12:277‐8.
SAD‐PD 2004 {published data only}
-
- Richard I, McDonald W, Pearson N, LaDonna K, Guerrette B, Hui J, et al. Study of antidepressants in Parkinson’s Disease (SAD‐PD). ClinicalTrials.gov 2004.
Zanardi 1996 {published data only}
-
- Zanardi R, Franchini L, Gasperini M, Perez J, Smeraldi E. Double‐blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. American Journal of Psychiatry 1996;153(12):1631‐3. - PubMed
References to studies awaiting assessment
29060/III/83/12 {unpublished data only}
-
- Glaxo SmithKline. A study to assess the effectiveness and tolerance of paroxetine by double blind comparison with placebo and mianserin. www.gsk‐clinicalstudyregister.com Accessed 26/10/2012.
Ballus 1997 {published data only}
-
- Ball s C, Quiros G, Flores T, Torre J, Palao D, Rojo L, et al. The efficacy and tolerability of venlafaxine and paroxetine in outpatients with mild to moderate depression or dysthimia. 10th European College of Neuropsychopharmacology Congress. Vienna, Austria. 1997.
-
- Ballus C, Quiros G, Flores T, Torre J, Palao D, Rojo L, et al. The efficacy and tolerability of venlafaxine and paroxetine in outpatients with mild to moderate depression or dysthimia. 11th European College of Neuropsychopharmacology Congress. Paris, France. 1998.
Benattia 2004 {published data only}
-
- Benattia I, Musgnung J, Graepel J. Treatment algorithms in depression: Remission with venlafaxine extended release versus SSRIs. 157th Annual Meeting of the American Psychiatric Association, New York, NY. 2004.
Blackwell 1967 {published data only}
-
- Blackwell B, Shepherd M. Early evaluation of psychotropic drugs in man. A trial that failed. Lancet 1967;2(520):819‐22. - PubMed
Chen 2001 {published data only}
-
- Chen H, Chen S, Li X, Lin J. A controlled study of the efficacy of venlafaxine capsules and paroxetine tablets in the treatment of depression. Herald of Medicine 2001;20(8):488‐9.
Deuschle 2003 {published data only}
-
- Deuschle M, Hamann B, Meichel C, Krumm B, Lederbogen F, Kniest A, et al. Antidepressive treatment with amitriptyline and paroxetine: effects on saliva cortisol concentrations. Journal of Clinical Psychopharmacology 2003;23(2):201‐5. - PubMed
-
- Deuschle M, Kniest A, Niemann H, Erb‐Bies M, Colla N, Hamann B, Heuser I. Impaired declarative memory in depressed patients is slow to recover: clinical experience. Pharmacopsychiatry 2004;37(4):147‐51. - PubMed
-
- Deuschle M, Krumm B, Bindeballe N, Colla M, Hamann B, Lederbogen F, et al. Open‐label non‐randomized versus double‐blind randomized antidepressive treatment: what are the advantages of clinical decision over randomization?. Pharmacopsychiatry 2004;37(6):299‐302. - PubMed
-
- Deuschle M, Luppa P, Gilles M, Hamann B, Heuser I. Antidepressant treatment and dehydroepiandrosterone sulfate: Different effects of amitriptyline and paroxetine. Neuropsychobiology 2004;50(3):252‐6. - PubMed
-
- Deuschle M, Luppa P, Hamann B, Nonell A, Heuser I. Increased concentration of corticosteroid‐binding globulin due to antidepressant treatment with amitritpyline, but not paroxetine. Journal of Psychiatric Research 2003;37(1):85‐7. - PubMed
Feng 2005 {published data only}
-
- Feng G, Xie W. A comparative study of paroxetine and clomipramine in the treatment of depression. Chinese Journal of Health Psychology 2005;13(1):35‐6.
Geiger 1998 {unpublished data only}
-
- Geiger ME, McCafferty J, Gergel I. Paroxetine: the preferred choice of patients in the treatment of depression.. 11th European College of Neuropsychopharmacology Congress. Paris, France. 1998.
-
- McCafferty JP, Oakes R, Gergel IP. Patient preference for paroxetine antidepressant medication. XXIst Collegium Internationale Neuro psychopharmacologicum, Glasgow, Scotland. 1998.
Gonul 1999 {unpublished data only}
-
- Gonul AS, Yabanoglu I, Reyhancan M, Oguz A. Selective serotonin reuptake inhibitors: discontinuation rates due to side effects. European Neuropsychopharmacology 1999;9(Suppl 5):215.
Gou 2002 {published data only}
-
- Gou Q, Feng E, Ren H. A clinical control study of venlafaxine and paroxetine in the treatment of depression. Journal of Chinese Civil Administration Medicine 2002;14(6):354‐5.
Guan 2001 {published data only}
-
- Guan N, Zhang J, Han Z. A study on quality of life and cost of treatment for depression with sertraline, fluoxetine and paroxetine. Chinese Journal of Behavioral Medical Science 2002;11(6):637‐8.
Gurovich 1997 {published data only}
-
- Gurovich IY, Shmukler AB, Storozhakova YA. Psycho‐social evaluation of antidepressive medication efficacy (quality‐of‐life approach). WPA Thematic Conf Jerusalem. 1997.
Han 2004 {published data only}
-
- Han Y, Ma Z, Wan Y. A controlled study of trazodone and paroxetine in the treatment of depression. Health Psychology Journal 2004;12(3):174‐5.
Hang 2005 {published data only}
-
- Hang R, Xu P, Wang R. A comparative study of mirtazapine and paroxetine in the treatment of depression. Shandong Archives of Psychiatry 2005;18(4):225‐6.
Henning 2002 {published data only}
-
- Henning O, Niedermaier N, Kniest A, Heuser I, Deuschle M. Amitriptyline and paroxetine: effects upon peripheral nervous system (PNS). Journal of Clinical Psychopharmacology 2002;22(2):229‐30. - PubMed
Huang 2006 {published data only}
-
- Huang K, Luo J, Ran J. Control study of paroxetine and imipramine in the treatment of depression. Medical Journal of Chinese People Health 2006;18(5):343‐55.
Jakitowicz 2000 {unpublished data only}
-
- Jakitowicz J, Nowicki Z, Pankewicz P, Wisniewski G. Pharmaco‐EEG profile of tianeptine (Coaxil) and paroxetine (Seroxat) in depressive patients. European Neuropsychopharmacology 2000;10(Suppl 2):51.
Lemoine 1998 {published data only}
-
- Lemoine P, Smeraldi E, Palomo T, Cosson J‐P, Zibellini M, Rico‐Villademoros F, Marcus RN. Nefazodone versus paroxetine in depressed outpatients. 151st Annual Meeting of the American Psychiatric Association. Toronto, Ontario, Canada. 1998.
Li 2001 {published data only}
-
- Li Z, Ma Y. A contrast study of paroxetine and amitriptyline in the treatment of depression. Journal of Henan University 2001;20(2):21‐2.
Li 2003 {published data only}
-
- Li W, Li Z, Lu J. A comparative study between paroxetine and amitriptyline in the treatment of depression. Shandong Archives of Psychiatry 2003;16(1):17‐8.
Li 2004 {published data only}
-
- Li Y, Zhang XN, Wu ZM. Comparative study on the effects of paroxetine and venlafaxine in treating depression. Chinese Journal of Clinical Rehabilitation 2004;8(21):4174‐5.
Li 2006 {published data only}
-
- Li D, Wang C, Yu J. A comparative study of citalopram and paroxetine in the treatment of depression. Medical Journal of Chinese People Health 2006;18(6):460‐1.
Liao 2002 {published data only}
-
- Liao R, Wen Y. Pharmcy‐economic evaluation of fluoxetine, paroxetine, and venlafaxine in treatment of major depression. Strait Pharmaceutical Journal 2002;14(6):80‐2.
Liu 2002 {published data only}
-
- Liu YH, Xu MX. A comparative study of paroxetine and amitriptyline in the treatment of senile melancholia. Journal of Linyi Medical College 2002;24(5):321‐3.
Liu 2005 {published data only}
-
- Liu W, Gao H. A study of venlafaxine and paroxetine in the treatment of depression. Medical Journal of Chinese People Health 2005;17(12):723‐4, 727.
Ma 2000 {published data only}
-
- Ma J, Wei H, Niu Y. Clinical comparative study on paroxetine in treatment of depression. Herald of Medicine 2000;19(2):144‐5.
Mertens 1988 {published data only}
-
- Mertens C, Pintens H. Paroxetine in the treatment of depression A double‐blind multicenter study versus mianserin. Acta Psychiatrica Scandinavica. 1988; Vol. 77, issue 6:683‐88. - PubMed
Montoya 1998 {published data only}
-
- Montoya F, Ontiveros A, Valdes M, Costilla A. Sexual dysfunction on imipramine and paroxetine. 151st Annual Meeting of the American Psychiatric Association. Toronto, Ontario, Canada. 1998.
-
- Ontiveros A, Lugoleos J. A double‐blind study with paroxetine and imipramine. 152nd Annual Meeting of the American Psychiatric Association, Washington, DC. 1999.
Peng 2004a {published data only}
-
- Peng J, Xu Y, Piao S. A comparative study of mirtazapine and paroxetine for depressed patients. Medical Journal of Chinese People Health 2004;16(11):664‐5.
Peng 2004b {published data only}
-
- Peng J, Xu Y, Piao S. A comparative study of tianeptine and paroxetine for depressive patients. Shandong Archives of Psychiatry 2004;14(4):195‐6, 199.
Qiao 2005 {published data only}
-
- Qiao J, Yu J, Hao Z. Comparative study of citalopram and paroxetine in treatment of depression. Journal of Clinical Psychological Medicine 2005;15(5):281‐2.
R228060 2004 {published data only}
-
- Anon. A 6‐ week, randomized, double‐blind, parallel‐group, active‐and placebo‐controlled trial to assess the efficacy of R228060 in adult subjects with major depressive disorder (MDD). ClinicalTrials.gov 2004.
Ren 2004 {published data only}
-
- Ren H, Guo Q, Cheng M. A study of mirtazapine and paroxetine in the treatment of depression. Journal of Clinical Psychological Medicine 2004;14(2):88‐9.
Salzman 1993 {unpublished data only}
-
- Salzman C, Jimerson D, Vasile R, et al. Predictors of serotonergic antidepressant response. Clinical Neuropharmacology 1992;15:437.
Serretti 2001 {published data only}
-
- Serretti A, Zanardi R, Galbusera E, Cusin C, Rossini D, Lattuada E, et al. Genetics of the response to antidepressants in mood disorders. Giornale Italiano di Psicopatologia 2001;7(3):244‐58.
Shu 2004 {published data only}
-
- Shu D, Zhang K, He H. Control study of paroxetine and amitriptyline in treatment of aged depression. Modern Medicine and Health 2011;20(5):311.
Song 2004 {published data only}
-
- Song R, Liu Y. A comparative study of paroxetine and mianserin in the treatment of senile depresison. Shandong Archives of Psychiatry 2004;17(3):144‐6.
Starmer 1996 {unpublished data only}
-
- Starmer G, Mascord D. Comparison of effects of paroxetine and amitriptyline on driving and psychomotor performance in depression. XXth Collegium Internationale Neuro psychopharmacologicum, Melbourne, Australia. 1996.
Su 2005 {published data only}
-
- Su H, Lei D, Yu H. Comparative study of mirtazapine and paroxetine in the treatment of depression. Modern Medicine and Health 2005;21(12):1480‐1.
Sun 2001 {published data only}
-
- Sun Z, Yu X. A comparative study of paroxetine and amitriptyline in the treatment of depression. Shandong Archives of Psychiatry 2001;14(4):226‐8.
Tao 2005 {published data only}
-
- Tao W, Lv C, Li W. A comparative study between citalopram and paroxetine in the treatment of depression. Medical Journal of Chinese People Health 2005;17(9):491‐2.
Tao 2006 {published data only}
-
- Tao L. Comparative study between tianeptine and paroxetine in treatment of depression. Journal of Clinical Psychological Medicine 2006;16(4):219‐20.
Wang 2003 {published data only}
-
- Wang Q, Zhou Z. A comparative study of fluoxetine, paroxetine and venlafaxine in the treatment of depression. Health Psychology Journal 2003;11(4):255‐6, 259.
Wang 2004 {published data only}
-
- Wang X, Ma A, Sun H. A comparative study of paroxetine versus tricyclic antidepressants for depression. Journal of Clinical Psychological Medicine 2004;14(1):14‐5.
Wang 2005 {published data only}
-
- Wang X, Zhou D. A comparative study of domestic and imported products of paroxetine on efficacy and safety in patients with major depression. Shanghai Archives of Psychiatry 2005;17(6):334‐6.
Wang 2007 {published data only}
-
- Wang D, Wang X, Li X. Comparison between the effects of fluoxetine and paroxetine on the life quality of the depressive disorder. Nervous Diseases and Mental Health 2007;7:23‐5.
Wieck 2001 {published data only}
-
- Wieck A. Reboxetine versus Paroxetine in treatment of major depressive disorder. National Research Register 2001.
Wu 2000 {published data only}
-
- Wu XQ, Yang LQ, Lu C, Xiong YY, Liu GX, Ma WT, et al. Comparson of paroxetine and doxepin in depressed patients: a double‐blind randomized study. Pharmaceutical Journal of Chinese People's Liberation Army 2000;16(1):20‐2.
Wu 2007 {published data only}
-
- Wu YS, Chen YC, Lu RB. Venlafaxine vs. paroxetine in the acute phase of treatment for major depressive disorder among Han Chinese population in Taiwan. Journal of Clinical Pharmacy and Therapeutics 2007;32(4):353‐63. - PubMed
Xie 1999 {published data only}
-
- Xie GR, Huang MS, Xue MT, Fan CH. A randomized double‐blind amitriptyline‐controlled study of paroxetine treatment for major depression. Chinese Journal Clinical Pharmacology 1999;15(1):18‐21.
Yang 1998 {published data only}
-
- Yang Q, Li J. Amitriptyline enhanced the effect of the selective serotonin reuptake inhibitors: A pilot trial. XXIst Collegium Internationale Neuro psychopharmacologicum, Glasgow, Scotland. 1998.
Yang 2004 {published data only}
-
- Yang JZ, Ma HB, Yang SE. Paroxetine vs amitriptyline in treating depression. Chinese Journal of New Drugs and Clinical Remedies 2004;23(5):293‐6.
Yang 2006 {published data only}
-
- Yang X, Wang H, Shao G. Comparative study of reboxetine and paroxetine in the treatment of depression. Journal of Clinical Psychosomatic Diseases 2006;12(6):413‐5.
Ye 2002 {published data only}
-
- Ye Q, Gu XY, Liu JF, Zhao YL. A clinical control study of venlafaxine and paroxetine in the treatment of depression in outpatients. Journal of Clinical Psychological Medicine 2002;12(2):84‐5.
Zhang 2003 {published data only}
-
- Zhang Y, Zhang J, Liang W. A comparative study of venlafaxine extended release vs. paroxetine in treatment of depression. Shanghai Archives of Psychiatry 2003;15(6):341‐3, 327.
Zhou 2005 {published data only}
-
- Zhou J, Xu X, Liu Y. A comparative study of paroxetine and imipramine in the treatment of depression. Medical Journal of Chinese People Health 2005;17(12):731‐2.
Zimbroff 2004 {published data only}
-
- Zimbroff DL, Bose A, Li D. Escitalopram treatment of SSRI nonresponders can lead to remission in patients who fail initial SSRI therapy. 157th Annual Meeting of the American Psychiatric Association, New York, NY. 2004.
Zou 2006 {published data only}
-
- Zou J, Jing Y, Song K, Hu Y. Comparative study on mirtazapine and paroxetine in the treatment of depression. Journal of Clinical Psychological Medicine 2006;16(4):235‐6.
References to ongoing studies
Additional references
Als‐Nielsen 2003
-
- Als‐Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?. JAMA 2003;290(7):921‐8. - PubMed
Altman 1996
Anderson 2000
-
- Anderson IM, Nutt DJ, Deakin JF. Evidence‐based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. Journal of Psychopharmacology 2000;14(1):3‐20. - PubMed
APA 1994
-
- American Psychiatric Association. .. Diagnostic and Statistical Manual of Mental Disorders (DSM‐IV). 4th Edition. Washington, DC: American Psychiatric Association, 1994.
APA 2000
-
- American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). American Journal of Psychiatry 2000;157(4 Suppl):1‐45. - PubMed
Barbui 2004
-
- Barbui C, Cipriani A, Brambilla P, Hotopf M. "Wish bias" in antidepressant drug trials?. Journal of Clinical Psychopharmacology 2004;24(2):126‐30. - PubMed
Barbui 2008
Begg 1996
-
- Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA 1996;276(8):637‐9. - PubMed
Bhandari 2004
Bollini 1999
-
- Bollini P, Pampallona S, Tibaldi G, Kupelnick B, Munizza C. Effectiveness of antidepressants. Meta‐analysis of dose‐effect relationships in randomised clinical trials. British Journal of Psychiatry 1999;174:297‐303. - PubMed
Buchkowsky 2004
-
- Buchkowsky SS, Jewesson PJ. Industry sponsorship and authorship of clinical trials over 20 years. Annals of Pharmacotherapy 2004;38(4):579‐85. - PubMed
Cipriani 2009
-
- Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, et al. Comparative efficacy and acceptability of 12 new‐generation antidepressants: a multiple‐treatments meta‐analysis. Lancet 2009;373:746‐58. - PubMed
Cipriani 2009a
Cipriani 2009b
Cipriani 2012a
Cipriani 2012b
Ciuna 2004
-
- Ciuna A, Andretta M, Corbari L, Levi D, Mirandola M, Sorio A, et al. Are we going to increase the use of antidepressants up to that of benzodiazepines?. European Journal of Clinical Pharmacology 2004;60(9):629‐34. - PubMed
Cohen 1992
-
- Cohen J. A power primer. Psychological Bulletin 1992;112(1):155‐9. - PubMed
Elbourne 2002
-
- Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140‐9. - PubMed
Ellis 2004
-
- Ellis P. Australian and New Zealand clinical practice guidelines for the treatment of depression. Australian and New Zealand Journal of Psychiatry 2004;38(6):389‐407. - PubMed
Feighner 1972
-
- Feighner JP, Robins E, Guze SB, Woodruff RA, Winokur G, Munoz R. Diagnostic criteria for use in psychiatric research. Archives of General Psychiatry 1972;26:57‐63. - PubMed
Furukawa 2002a
-
- Furukawa TA, Guyatt GH, Griffith LE. Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta‐analyses. International Journal of Epidemiology 2002;31(1):72‐6. - PubMed
Furukawa 2002b
Furukawa 2005
-
- Furukawa TA, Cipriani A, Barbui C, Brambilla P, Watanabe N. Imputing response rates from means and standard deviations in meta‐analysis. International Clinical Psychopharmacology 2005;20(1):49‐52. - PubMed
Furukawa 2006
-
- Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta‐analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(1):7‐10. - PubMed
Furukawa 2007
-
- Furukawa TA, Watanabe N, Omori IM, Montori VM, Guyatt GH. Association between unreported outcomes and effect size estimates in Cochrane meta‐analyses. JAMA 2007;297(5):468‐70. - PubMed
Gartlehner 2011
-
- Gartlehner G, Hansen RA, Reichenpfader U, Kaminski A, Kien C, Strobelberger M, et al. Drug Class Review: Second‐Generation Antidepressants: Final Update 5 Report. Drug Class Reviews 2011. - PubMed
Germann 2013
-
- Germann D, Ma G, Han F, Tikhomirova A. Paroxetine hydrochloride. Profiles of Drug Substances, Excipients, and Related Methodology 2013;38:367‐406. - PubMed
Gibiino 2012
-
- Gibiino S, Serretti A. Paroxetine for the treatment of depression: a critical update. Expert Opinion on Pharmacotherapy 2012;13(3):421‐31. - PubMed
Guy 1970
-
- Guy W, Bonato RR. Manual for the ECDEU Assessment Battery.2. Chevy Chase, MD: National Institute of Mental Health, 1970.
Hamilton 1960
Hansen 2005
-
- Hansen RA, Gartlehner G, Lohr KN, Gaynes BN, Carey TS. Efficacy and safety of second‐generation antidepressants in the treatment of major depressive disorder. Annals of Internal Medicine 2005;143(6):415‐26. - PubMed
Higgins 2003
Higgins 2011
-
- Higgins JP, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. Chichester: John Wiley & Sons, Ltd, 2011.
Hróbjartsson 2013
-
- Hróbjartsson A, Thomsen AS, Emanuelsson F, Tendal B, Hilden J, Boutron I, et al. Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors. Canadian Medical Association Journal 2013;ahead of print:1‐11. - PMC - PubMed
Ioannidis 2008
-
- Ioannidis JP. Interpretation of tests of heterogeneity and bias in meta‐analysis. Journal of Evaluation in Clinical Practice 2008;14(5):951‐7. - PubMed
Jüni 2001
Khan 2003
-
- Khan A, Khan SR, Walens G, Kolts R, Giller EL. Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports. Neuropsychopharmacology 2003;28(3):552‐7. - PubMed
Langendam 2013
Lexchin 2003
Luborsky 1962
-
- Luborsky L. Clinician's judgments of mental health. Archives of General Psychiatry 1962;7:407‐17. - PubMed
Lundh 2012
Magni 2013
Montgomery 1979
-
- Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry 1979;134:382‐9. - PubMed
Montgomery 2004b
-
- Montgomery JH, Byerly M, Carmody T, Li B, Miller DR, Varghese F, et al. An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia. Controlled Clinical Trials 2004;25(6):598‐612. - PubMed
Nakagawa 2009
NICE 2010
-
- National Institute for Clinical Excellence. Depression: management of depression in primary and secondary care ‐ NICE guidance. National Institute for Clinical Excellence. National Institute for Clinical Excellence, 2010.
Omori 2010
Oxman 1992
-
- Oxman AD, Guyatt GH. A consumer's guide to subgroup analyses. Annals of Internal Medicine 1992;116(1):78‐84. - PubMed
Perlis 2005
-
- Perlis RH, Perlis CS, Wu Y, Hwang C, Joseph M, Nierenberg AA. Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. American Journal of Psychiatry 2005;162(10):1957‐60. - PubMed
Procyshyn 2004
-
- Procyshyn RM, Chau A, Fortin P, Jenkins W. Prevalence and outcomes of pharmaceutical industry‐sponsored clinical trials involving clozapine, risperidone, or olanzapine. Canadian Journal of Psychiatry ‐ Revue Canadienne De Psychiatrie 2004;49(9):601‐6. - PubMed
Purgato 2010
-
- Purgato M, Barbui C, Cipriani A. Assessing risk of bias in randomized controlled trials. Epidemiologia e Psichiatria Sociale 2010;19(4):296‐7. - PubMed
RevMan 2012 [Computer program]
-
- The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
Savović 2012
-
- Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine 2012;157(6):429‐38. - PubMed
Schulz 1995
-
- Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408‐12. - PubMed
Spitzer 1972
-
- Spitzer RL, Endicott J, Robins E. Research diagnostic criteria: rationale and reliability. Archives General Psychiatry 1978;35(6):773‐82. - PubMed
Sterne 2000
-
- Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta‐analysis: power of statistical tests and prevalence in the literature. Journal of Clinical Epidemiology 2000;53(11):1119‐29. - PubMed
Turner 2012
-
- Turner L, Shamseer L, Altman DG, Weeks L, Peters J, Kober T, et al. Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals. Cochrane Database of Systematic Reviews 2012, Issue 11. [DOI: 10.1002/14651858.MR000030.pub2] - DOI - PMC - PubMed
Ware 1993
-
- Ware JE, Snow KK, Kosinski M, & Gandek B. SF‐36 Health Survey Manual and Interpretation Guide. Boston, MA: New England Medical Centre, 1993.
Watanabe 2011
WHO 1992
-
- World Health Organization. The Tenth Revision of the International Classification of Diseases and Related Health Problems (ICD‐10). Geneva: World Health Organization, 1992.
WHO 2006
-
- World Health Organization. WHO Collaborative Centre for Drug Statistics Methodology. http://www.whocc.no/atcddd/.
WHOQOL Group 1998
-
- WHOQOL Group. The World Health Organization quality of life assessment (WHOQOL): Development and general psychometric properties. Social Science and Medicine 1998;46(12):1569‐85. - PubMed
Wing 1994
-
- Wing J. Measuring mental health outcomes: a perspective from the Royal College of Psychiatrists. Outcomes into Clinical Practice. London: British Medical Journal Publishing, 1994.
Wood 2008
Zimmerman 2004
-
- Zimmerman M, Posternak MA, Chelminski I. Derivation of a definition of remission on the Montgomery‐Asberg depression rating scale corresponding to the definition of remission on the Hamilton rating scale for depression. Journal of Psychiatric Research 2004;38(6):577‐82. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
